Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

Antonio Cuadrado¹, Ana I. Rojo¹, Geoffrey Wells², John D. Hayes³, Sharon P. Cousin⁴, William L. Rumsey⁵, Otis C. Attucks⁶, Stephen Franklin⁷, Anna-Liisa Levonen⁸, Thomas W. Kensler⁹ and Albena T. Dinkova-Kostova³,¹⁰ *

¹ Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Investigación Sanitaria La Paz (IdiPaz), Department of Biochemistry and Instituto de Investigaciones Biomédicas Alberto Sols UAM-CSIC, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain. Victor Babes National Institute of Pathology, Bucharest, Romania
² UCL School of Pharmacy, 29/39 Brunswick Square, University College London, London, WC1N 1AX, United Kingdom
³ Jacqui Wood Cancer Centre, Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 9SY, Scotland, United Kingdom
⁴ Reata Pharmaceuticals, Irving, Texas, USA
⁵ GSK, Collegeville, PA, USA
⁶ vTv Therapeutics, 4170 Mendehall Oaks Parkway, High Point, NC 27265, USA
⁷ Evgen Pharma plc., The Colony, Altrincham Road, Wilmslow, Cheshire, SK9 4LY, United Kingdom
⁸ A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniemietie 2, Kuopio FI-70211, Finland
⁹ Translational Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
¹⁰ Department of Pharmacology and Molecular Sciences and Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

* To whom correspondence should be addressed:
Albena T. Dinkova-Kostova
Jacqui Wood Cancer Centre, Division of Cellular Medicine, School of Medicine, University of Dundee, James Arrott Drive, Dundee DD1 9SY, Scotland, United Kingdom
Email: a.dinkovakostova@dundee.ac.uk
Abstract

Transcription factor NF-E2 p45-related factor 2 (NRF2, gene name NFE2L2) and its principal negative regulator, the E3 ligase adapter Kelch-like ECH-associated protein 1 (KEAP1), play a critical role in the development and progression of chronic diseases of the lung and liver, autoimmune, neurodegenerative and metabolic disorders, and also cancer. NRF2 activation provides cytoprotection against numerous pathologies characterized by chronic inflammation, metabolic alterations and redox disturbances. One NRF2 activator has received clinical approval and several electrophilic modifiers of the cysteine-based sensor KEAP1 and inhibitors of its interaction with NRF2 are now in clinical development. However, challenges regarding target specificity, pharmacodynamic properties, efficacy, and safety remain.

Introduction

Transcription factor NRF2 was discovered in 1994 as a member of the human cap’n’collar (CNC) basic-region leucine zipper transcription factor family. Subsequent work, including the generation of NRF2-knockout mice, established that NRF2 regulates the expression of about 250 genes that contain an enhancer sequence in their promoter regulatory regions that is termed the Antioxidant Response Element (ARE). These genes encode a network of cooperating enzymes involved in endobiotic and xenobiotic biotransformation reactions, antioxidant metabolism, intermediate metabolism of carbohydrates and lipids, iron catabolism, protein degradation and regulators of inflammation. Through this transcriptional network, NRF2 is able to coordinate a multifaceted response to diverse forms of stress, enabling maintenance of a stable internal environment.
In 1999, Kelch-like ECH-associated protein 1 (KEAP1) was identified as a repressor of NRF2, and a further 5 years elapsed before it was reported to be an E3 ubiquitin ligase substrate adaptor that targets NRF2 for rapid proteasomal degradation. Thus, KEAP1 ensures that under unstressed conditions NRF2 is a protein of low abundance with a limited half-life of only about 15-40 min, depending on the cell type. Importantly however, KEAP1 contains several highly reactive cysteines that upon modification by electrophilic molecules prevent it from targeting NRF2 for proteasomal degradation, thereby resulting in rapid nuclear accumulation of NRF2 protein upon redox stress and, following dimerization with small musculoaponeurotic fibrosarcoma oncogene homolog (sMAF) proteins, induction of ARE-containing genes by NRF2-sMAF.

It is now widely recognized that because of the versatile and comprehensive cytoprotective roles of the proteins encoded by NRF2 target genes, including anti-oxidant, detoxification and anti-inflammatory proteins, a functional NRF2/KEAP1 axis is essential for protection against a plethora of diseases that have oxidative stress and inflammation as underlying pathological features. These include metabolic and inflammatory/autoimmune disorders, diseases of the lung, liver, kidney, gastrointestinal tract, and cardiovascular system, as well as neurological conditions. The experimental evidence for the protective effects of NRF2 in these non-neoplastic diseases will be discussed later in this review. We will also address the role of NRF2 in cancer, which is a matter of intense research.

A three-dimensional reconstruction structure of the KEAP1 dimer obtained by single particle electron microscopy shows that the protein has a forked-stem structure comprising two large spheres that enclose the intervening (IVR), Kelch, and C-terminal-region domains, where dimerization is mediated by the BTB domain (Figure 1A). Bearing in mind that KEAP1 contains a number of distinct and autonomously functioning
cysteine sensors (C151, C226, C273, C288 and C613)\textsuperscript{14-16}, the existing evidence suggests that NRF2 and KEAP1 integrate nitric oxide, Zn\textsuperscript{2+} and alkenal signaling with redox signaling, and that together they also provide a mechanism that probably evolved, at least in part, to allow rapid adaptation to exposure to phytochemicals encountered in the diet. Many plant-derived electrophilic xenobiotics activate the NRF2/KEAP1 axis to elicit cytoprotective responses, with the highly reactive cysteines in KEAP1 acting as the immediate sensors\textsuperscript{17-19}. The high reactivity of these sensors with electrophiles allows for therapeutic KEAP1 targeting in the absence of unspecific thiol modifications (Figure 1B). Therefore a wealth of naturally-occurring inducers of NRF2-target genes has been described\textsuperscript{20}, and new inducing agents continue to be discovered.

Whilst a substantial number of academic laboratories have been involved in identification of NRF2 activators, historically the engagement of pharmaceutical companies in this exciting and promising field has been relatively low key. This possible reticence of industry to consider the NRF2/KEAP1 axis as a valuable drug target may be due in part to its wide spectrum of biochemical activities, beyond merely controlling antioxidant systems, which are regulated either directly or indirectly by NRF2. The diverse direct and indirect effects of NRF2 activators are sometimes interpreted as evidence for non-specific effects. However, the evolution of several distinct thiol-based redox switches within KEAP1 that allow mammalian species to adapt to a wide spectrum of phytochemicals provides a rationale for changing the perception that activation of NRF2 elicits certain “off-target” effects, and to adopt a broader view that activation of NRF2 elicits beneficial “multi-target” cytoprotective effects\textsuperscript{11}. In particular, the “multi-target” benefits of NRF2 activation include maintenance of redox signaling, enhanced xenobiotic biotransformation, control and resolution of inflammation, suppression of gluconeogenesis and hepatic lipogenesis,
support of proteostasis, and suppression of fibrosis. In this context, it is noteworthy that most chronic diseases, particularly those confined to the aged population, do not have a unique etiology, nor do they exhibit a single pathophenotype, and as such they may be most effectively treated with drugs that activate NRF2. Indeed, stimulation of broad cytoprotective mechanisms upon NRF2 activation is less likely to be effectively overwhelmed or circumvented by pathogenic processes than are more specifically-targeted therapeutic interventions.

This expanded recognition of NRF2 as a potential drug target has sparked the interest of the pharmaceutical industry and led to a substantial investment in the clinical development of NRF2 modulators. The NRF2 activator dimethyl fumarate (DMF, trade names, Fumaderm or Tecfidera) is now clinically used to treat psoriasis and remitting relapsing multiple sclerosis (Table 1), and its current distribution remains a hallmark that other pharmaceutical companies hope to achieve. Currently, a number of NRF2 activators of several distinct chemical classes are at various stages of clinical development, such as the KEAP1 cysteine-targeting fumaric acid derivatives, the isothiocyanate sulforaphane, cyanoenone triterpenoids, nitro fatty acids, and hydroxylamine. Additional drug candidates include non-electrophilic compounds that disrupt the NRF2/KEAP1 protein-protein interactions, as well as molecules with KEAP1-independent modes of action. Inhibitors of NRF2 are also being pursued, but are not yet in clinical trials. This review provides an overview of these drug candidates and highlights the unusual nature and the critical importance of context for targeting the NRF2/KEAP1 axis. The physiological roles of NRF2 in cellular redox, metabolic and protein homeostasis, and in resolution of inflammation are described, and experimental evidence for the protective role of NRF2 in non-neoplastic disease is presented. The advantages and limitations of the various small
molecule pharmacological modulators of NRF2 activity that are in clinical development are assessed. Finally, ongoing challenges associated with the development of NRF2 modulators, including target specificity, pharmacodynamics assessment, bioavailability, efficacy, and safety are highlighted.

**Physiological roles of the NRF2/KEAP1 axis**

*Redox, metabolic and protein homeostasis*

Since its initial discovery in the participation of biotransformation reactions, in which it regulates the expression of certain cytochrome P450 oxidoreductases, conjugating enzymes and ABC transporters (Table 2), it has become increasingly apparent that NRF2 is involved in control of the redox environment, culminating in recognition of the NRF2/KEAP1 axis as a ‘thiol-driven master switch’ that is used for ‘system-wide oxidative stress responses’\(^{22}\). NRF2 regulates the expression of the four genes (glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, malic enzyme 1, and isocitrate dehydrogenase 1) involved in the generation of NADPH, the critical cofactor that fuels antioxidant reactions\(^{23-26}\). The supply of this reducing equivalent is further used by a plethora of redox reactions, many of which are also regulated by NRF2. Thus, NRF2 regulates the expression of critical enzymes involved in the synthesis and use of the redox buffer reduced glutathione (GSH, the oxidized form of which is GSSG), such as the catalytic and modulator subunits of glutamate-cysteine ligase, glutathione reductase, glutathione peroxidase and several glutathione S-transferases\(^4\). Moreover, many ancillary proteins within the redoxin family such as thioredoxin, thioredoxin reductase, peroxiredoxin and sulfiredoxin, are all regulated by NRF2, and provide compartmentalized sensing and signal transduction of regional production of reactive oxygen species (ROS, i.e., hydrogen
peroxide, the hydroxyl radical and the superoxide radical\textsuperscript{27-29}. Besides these direct effects on redox status, NRF2 regulates genes encoding enzymes that prevent quinones from participating in redox cycling reactions and glutathione depletion (by NAD(P)H:quinone oxidoreductase-1 (NQO1)) or are involved in the indirect production of bilirubin (heme oxygenase 1, HMOX1; biliverdin reductase, BVR), which is the most potent non-polar physiological antioxidant\textsuperscript{30}. Finally, through crosstalk with the pentose phosphate pathway and glycolysis, NRF2 affects intermediary metabolism and increases the availability of substrates and reducing equivalents for the mitochondrial respiratory chain\textsuperscript{31}, as well as for maintaining integrity of mitochondrial DNA (mtDNA)\textsuperscript{32}.

NRF2 participates in the clearance of oxidized, or otherwise damaged, proteins and organelles during redox alterations or nutritional starvation. Thus, the autophagy transporter sequestosome 1 (SQSTM1/p62), which interacts with ubiquitinated cargo via its ubiquitin association (UBA) domain and recruits them into the autophagosome via its LC3-interacting motif, is an NRF2 transcriptional target\textsuperscript{33,34}. In addition, KEAP1 binds to p62\textsuperscript{33,35}, and a recent study has found that KEAP1/Cul3 ubiquitinates p62 at lysine-420 within its UBA domain, thereby facilitating the sequestration activity of p62\textsuperscript{36}. Within its primary structure, p62 contains an ETGE-like motif, STGE, which upon phosphorylation by mTORC1 generates the recognition site for docking to KEAP1\textsuperscript{37}. Then, KEAP1 is transported to the autophagosome for degradation, thus allowing accumulation of NRF2\textsuperscript{38}. Moreover, several autophagy genes appear to contain ARE sequences in their promoter regions, and it has been reported that NRF2 activates both chaperone-mediated autophagy\textsuperscript{39} and macroautophagy\textsuperscript{40,41}. Other roles of NRF2 in proteostasis under oxidative conditions are demonstrated by its activation by the unfolded protein response\textsuperscript{42,43} and its ability to regulate proteasome subunit expression\textsuperscript{44,45}. 
At least in brain and blood, the abundance of mRNA encoding NRF2 is higher than that for KEAP1 (Figure 2) and by contrast the half-life of the KEAP1 protein is longer than that of NRF2 (Table 2). These observations highlight the different turnover rates of both proteins: slow for KEAP1; fast for NRF2. Moreover, although NRF2 and KEAP1 are ubiquitously expressed, specific cell types are predominantly in charge of homeostatic adaptations and present different levels of expression (Figure 2). Thus, monocytes and neutrophils exhibit the highest levels of NRF2 among blood cells, suggesting an immunomodulatory effect of the innate immune system (see below). In the brain, crosstalk between astrocytes and neurons couples intermediate metabolism with redox homeostasis, at least in part through NRF2. Moreover, glutamatergic neurotransmission in neurons leads to production of ROS that are controlled by the neuronal GSH pool. When this pool is low, neighboring astrocytes contribute to its restoration by providing neurons with the GSH precursors glycine, glutamate/glutamine and cysteine. Not surprisingly, NRF2 levels are high in astrocytes (Figure 2). Moreover, microglia as part of the monocyte lineage expresses high levels of NRF2 compared to neurons.

Resolution of inflammation

NRF2 is abundant in monocytes and granulocytes (Figure 2), suggesting its involvement in immune responses driven by these cell types. NRF2-knockout mice are hypersensitive to septic shock, and display persistent inflammation during wound healing, whereas genetic or pharmacological activation of NRF2 suppresses production of pro-inflammatory cytokines. In human cells, disruption of KEAP1, protected against sepsis by attenuating the inflammatory response of myeloid leukocytes and macrophages. Of particular interest, a polymorphism in NFE2L2 that is associated with reduced transcriptional activity
correlated with increased risk of inflammatory bowel disease\textsuperscript{59} and chronic gastritis\textsuperscript{60}. As indicated below, the robust anti-inflammatory activity of NRF2 has been attributed to at least three independent mechanisms: 1, modulation of redox metabolism; 2, crosstalk with nuclear factor-kappaB (NF-κB); 3, direct regulation of pro-inflammatory genes.

Inflammation is associated with increased local and systemic accumulation of pathological levels of ROS that may impair redox signaling\textsuperscript{61}. Mitochondrial dysfunction and uncontrolled activation of NADPH oxidase represent the main contributors to heightened ROS production in inflammatory cells, and mitochondrial ROS cause damage and release of mtDNA, thus creating a vicious cycle of events leading to further ROS production and activation of the inflammasome, ultimately resulting in organ debilitation\textsuperscript{62}. The redox-regulating activity of NRF2 represents an important break on the vicious cycle that prevents exacerbated inflammation and subsequent tissue damage\textsuperscript{63}.

NF-κB and NRF2 engage in crosstalk. Several functional NF-κB binding sites have been identified in the \textit{NFE2L2} gene promoter\textsuperscript{64}. On the other hand, NRF2 inhibits NF-κB transcriptional activity. Treatment of NRF2-deficient mice with lipopolysaccharide (LPS) or TNF-α increased the expression of the NF-κB transcriptional signature, suggesting an inhibitory role of NRF2 on NF-κB\textsuperscript{48}. A possible interpretation of this finding is that the inhibitor of NF-κB (IκB) is highly phosphorylated in NRF2-deficient cells and subject to rapid proteasomal degradation, thereby diminishing inhibition of NF-κB\textsuperscript{48}. Additionally, LPS was shown to activate simultaneously both a fast NF-κB-mediated response and a slow NRF2-mediated response, with the initial pro-inflammatory response being driven by NF-κB which was then subsequently inhibited when NRF2 activity was maximal\textsuperscript{65}. Other mechanisms by which the NRF2/KEAP1 axis suppresses NF-κB signaling include
competition between NRF2 and p65 for binding to p300\(^{66}\) and degradation of IκB kinase (IKK)\(\beta\) by KEAP1\(^{67,68}\).

Several macrophage-specific genes contain ARE sequences and are therefore regulated by NRF2. These include MARCO, a receptor required for bacterial phagocytosis, and CD36, a scavenger receptor for oxidized low-density lipoproteins\(^{69,70}\). On the other hand, NRF2 binds to regulatory regions of pro-inflammatory genes encoding IL-6 and IL-1\(\beta\) in an ARE-independent manner and prevents the recruitment of RNA Pol II to start transcription\(^{52}\).

Recent studies have provided a connection between macrophage metabolism and anti-inflammatory responses elicited by NRF2. The mitochondrial metabolite itaconate is produced from the TCA cycle in response to pro-inflammatory stimuli and increases profoundly during macrophage activation\(^{71,72}\). In turn, itaconate alkylates several KEAP1 cysteine sensors, including the critical C151, C273 and C288 residues, thereby activating NRF2 and suppressing transcription of pro-inflammatory cytokines, such as IL-6 and IL-1\(\beta\)\(^{71}\). Therefore, itaconate is an endogenous regulator of KEAP1 that acts as an ‘off-switch’ during the resolution of inflammation. In addition, activation of NRF2 by the cell-permeable itaconate derivative, 4-octyl-itaconate or sulforaphane represses the expression of the adaptor molecule stimulator of interferon genes (STING) by decreasing its mRNA stability, and consequently suppresses type-I interferon production\(^{73,74}\).

**The NRF2/KEAP1 axis in non-neoplastic disease**

A wealth of information has been generated in cellular and animal models about the role of NRF2 in providing protection against numerous chronic diseases, with many investigations
employing NRF2-knockout mice\textsuperscript{75}. Regarding humans, a recent study provided a basis to analyze the contribution of NRF2 in combating chronic disease using a Systems Medicine approach and, based on the connectivity of NRF2 with other molecules (NRF2-interactome) along with empirical evidence, established a first map of NRF2-related diseases (NRF2-diseasome)\textsuperscript{9}. Compelling evidence for a role of NRF2 in determining the susceptibility of humans to chronic disease is continually being provided by association studies between functional genetic variations of \textit{NFE2L2} and disease risk\textsuperscript{76-78}. Moreover, these genetic studies support the hypothesis that drugs mimicking small changes in NRF2 expression reported for some functional variations of \textit{NFE2L2} may be of therapeutic value. Below we will briefly describe some milestones in understanding the involvement of NRF2 in human chronic disease and highlight the available genetic evidence.

\textit{Autoimmune disease}

Oxidative tissue damage and apoptosis lead to the formation of haptens or damaged macromolecules that increase the risk of autoimmune reactions. Since NRF2-regulated enzymes play a critical role in detoxification of many chemicals, it provides a protective mechanism against the environmental susceptibility to autoimmune pathogenesis\textsuperscript{79}. Moreover, NRF2 suppresses pro-inflammatory Th1 and Th17 responses and activates immunosuppressive Treg and Th2 cells\textsuperscript{80}. The relevance of NRF2 in autoimmunity has been extensively studied in experimental autoimmune encephalomyelitis (EAE), which is a mouse model for MS, a chronic inflammatory disease characterized by infiltration of autoreactive immune cells into the central nervous system. In an EAE mouse model, the absence of NRF2 exacerbates disease\textsuperscript{81} whereas knockdown of KEAP1\textsuperscript{52} or treatment with a range of NRF2 activators, including cyanoenone triterpenoids\textsuperscript{82} and sulforaphane\textsuperscript{83},
attenuate its severity. In humans, gene expression profiling in IFN-1β-treated patients identified NRF2 as a potential mediator of long-term antioxidant response and neuronal preservation. As described below, several biopharmaceutical companies are exploiting the strong evidence that activation of NRF2 is of therapeutic value in MS. Indeed, the only NRF2 activator so far approved by the FDA and the EMA, dimethyl fumarate, is being marketed by Biogen for the treatment of remitting relapsing MS and psoriasis. A protective role for NRF2 has been suggested in other autoimmune diseases such as systemic lupus erythematosus, Sjogren’s syndrome, rheumatoid arthritis, vitiligo, and STING-dependent interferonopathies.

**Respiratory disease**

The lung responds to a variety of environmental toxicants, including smoke, by releasing pro-inflammatory cytokines and chemokines. This primary effect generates a progressive low-grade inflammatory response through the recruitment of circulating monocytes, neutrophils and T cells that release additional inflammatory mediators, ROS and metalloproteases. The end result is a vicious cycle of damage to lung parenchyma that leads to chronic obstructive pulmonary disease (COPD) or emphysema. NRF2 attenuates the burden to lung parenchyma caused by ROS and inflammation. Cigarette smoke is a major risk factor for the development of COPD and emphysema. 

*Nrf2*−/− mice are much more sensitive to the development of cigarette smoke-induced emphysema than their wild-type counterparts. Furthermore, the development of emphysema following chronic exposure to cigarette smoke was associated with a decline in the expression of cytoprotective genes, whereas the pentacyclic cyanoenone CDDO-imidazolide protected the lungs of *Nrf2*+/+, but not *Nrf2*−/− mice, against cigarette smoke-
induced oxidative stress, alveolar cell apoptosis, alveolar destruction, and pulmonary hypertension. Genetic upregulation of NRF2 (by Keap1 deletion in Clara cells, which are abundant in murine upper airways) has a similar protective effect.

In humans, the NRF2 transcriptional signature was decreased in alveolar macrophages from patients with smoking-related lung emphysema as compared with patients without emphysema. The human NFE2L2 gene promoter contains a haplotype comprising 3 single nucleotide polymorphism (SNP) sequences and 1 triplet repeat polymorphism that result in modulation of NRF2 expression. COPD patients with low to medium promoter activity were more prone to developing respiratory failure. Pharmacological activation of NRF2 by sulforaphane, or a compound that disrupts the interaction of KEAP1 with NRF2, reversed the impaired bacterial phagocytosis by cultured alveolar macrophages and monocyte-derived macrophages isolated from patients with COPD. However, daily oral administration of sulforaphane (extracted from broccoli sprouts) to COPD patients did not result in consistent changes in NRF2-dependent gene expression or markers of inflammation in alveolar macrophages and bronchial epithelial cells at the doses used, illustrating some of the challenges in translating findings from cell culture studies to humans. Patients with other chronic lung diseases, such as idiopathic pulmonary fibrosis, chronic sarcoidosis and hypersensitivity pneumonitis, were found to exhibit increased NRF2 expression and augmented levels of endogenous antioxidants in bronchoalveolar lavage fluids, suggesting an unsuccessful adaptive response to pathological ROS levels.

In agreement with the human data, Nrf2-/- mice are much more sensitive to the development of cigarette smoke-induced emphysema than their wild-type counterparts. Furthermore, the development of emphysema following chronic exposure to cigarette smoke...
smoke was associated with a decline in the expression of cytoprotective genes\textsuperscript{95}, whereas the pentacyclic cyanoenone CDDO-imidazolide protected the lungs of Nrf2\textsuperscript{+/+}, but not Nrf2\textsuperscript{−/−} mice, against cigarette smoke-induced oxidative stress, alveolar cell apoptosis, alveolar destruction, and pulmonary hypertension\textsuperscript{96}. Genetic upregulation of NRF2 (by Keap1 deletion in Clara cells, which are abundant in murine upper airways) has a similar protective effect\textsuperscript{97}.

\textit{Gastro-intestinal disease}

The gastro-intestinal (GI) tract is constantly exposed to xenobiotic challenges that can lead to formation of pathological levels of ROS and may provoke inflammatory bowel disease (IBD)\textsuperscript{103}. The GI tract is also one of the sites where pharmacological NRF2 activation by dietary agents and their synthetic analogs is highly prominent\textsuperscript{23,104-106}. In mice, dextran sulfate sodium-induced experimental colitis elicits more profound IBD in NRF2-deficient mice than in their wild-type counterparts\textsuperscript{107}. In humans, the relevance of NRF2 in adaptation of enterocytes to inflammatory stress was demonstrated in a comprehensive transcriptome study on IBD patients that evidenced its role in attenuation of the stress response of macrophages in the gut\textsuperscript{108}. Importantly, a genetic association has been found in a Japanese cohort of patients between a particular SNP in the NFE2L2 gene and the risk of developing ulcerative colitis\textsuperscript{109}. The functional haplotype of the three SNPs in the NFE2L2 promoter with slightly reduced expression of NRF2 was associated with development of gastric mucosal inflammation and peptic ulcer in association with \textit{H. pylori} infection\textsuperscript{60}.

The liver represents a first line of defense against food xenobiotics and orally-active drugs because a major portion of blood draining the GI tract is directed to the liver via the hepatic portal vein. Early work with Nrf2\textsuperscript{+/−} mice demonstrated the hepatoprotective effect
of NRF2 against acetaminophen\textsuperscript{110}, as did genetic activation of NRF2\textsuperscript{111}. As possibly anticipated, Nrf2\textsuperscript{-/-} mice fed alcohol (4-7 days) are markedly more susceptible to fatty liver aggravated hepatic inflammatory responses and liver failure than are similarly fed wild-type mice, and this is in part likely due to activation of the SREBP lipogenic transcription factor and a relative inability to detoxify acetaldehyde\textsuperscript{112}. The observation that disruption of NRF2 in mice impeded liver regeneration following partial heptectomy led to the discovery that NRF2 regulates the gene expression of Notch1\textsuperscript{113}, a mechanism that is also involved in the NRF2-mediated improvement of hematopoietic stem progenitor cell function and myelosuppression following exposure to ionizing radiation\textsuperscript{114}. In a mouse model of hereditary hemochromatosis with iron overload (due to mutation of the Homeostatic Iron Regulator gene), knockout of NRF2 increased necro-inflammatory lesions within livers of the knockout mice that led to hepatic fibrosis\textsuperscript{115}. Consistent with these observations, patients with primary biliary cholangitis and cirrhosis exhibit reduced NRF2 expression\textsuperscript{116}.

**Metabolic disease**

Metabolic disease, also referred to as metabolic syndrome, is typified by abdominal obesity, hypertension, hypertriglyceridemia, low high-density lipoprotein and fasting hyperglycemia. It is closely linked with type-2 diabetes mellitus (T2DM) and associated comorbidities such as vascular dysfunction, cardiovascular disease, glomerulonephritis, NASH (see above) and cognitive impairment. Although T2DM and its comorbidities are characterized by overproduction of superoxide by mitochondria\textsuperscript{117}, NRF2-null mice do not spontaneously develop diabetes. Indeed, the knockout mice exhibit increased insulin sensitivity, which has been attributed to ROS-mediated inhibition of protein tyrosine kinase
phosphatase 1B that antagonizes insulin signaling\(^\text{118}\). By contrast, genetic activation of NRF2 by knockout/knockdown of KEAP1 in mice on a \(db/db\) background, or pharmacological activation of NRF2 in \(db/db\) mice, suppress the onset of T2DM\(^\text{119}\). It therefore seems likely that when pancreatic beta cells are metabolically challenged to synthesize insulin in response to hyperglycemia, the resulting ROS burden may cause oxidative damage that impairs the response, leading to T2DM\(^\text{120,121}\). If this conclusion is correct, it is likely that improved pancreatic function contributes significantly to the improved glucose disposal observed following pharmacological activation of NRF2 by TBE-31 or sulforaphane in mice with diet-induced T2DM\(^\text{122,123}\), and in the reduction of fasting blood glucose and glycated hemoglobin (HbA1c) by sulforaphane-rich broccoli sprout extracts in obese patients with dysregulated T2DM\(^\text{123}\). Besides imparting increased resilience to oxidative stress on pancreatic beta cells, NRF2 activation may contribute to improved whole-body glucose homeostasis by suppressing glycogen breakdown in skeletal muscle through increasing expression of glycogen branching enzyme and phosphorylase \(b\) kinase \(\alpha\)\(^\text{119}\). In mouse models of diabetic nephropathy, pharmacological activation of NRF2 by sulforaphane or cinnamic aldehyde has been shown to suppress oxidative stress, transforming growth factor-\(\beta1\) signaling and fibrosis\(^\text{124}\).

It seems likely that NRF2 plays a key role in insulin resistance as suggested by the fact that its expression is low in monocytes of diabetic patients\(^\text{125}\). Compelling evidence comes from genetic association studies indicating that some \(NFE2L2\) polymorphisms that result in low NRF2 expression lead to pathological ROS levels and increased risk of T2DM\(^\text{126-128}\). Regarding complications, a failure of antioxidant protection due to
demethylation of the CpG islands in the \textit{KEAPI} promoter has been linked to diabetic cataracts\textsuperscript{129}.

NRF2 may also be protective against the development of nonalcoholic steatohepatitis (NASH). In a mouse model of NASH that involves administration of a methionine- and choline-deficient diet, NRF2-null mice succumbed to the disease much more rapidly than did wild type mice\textsuperscript{130,131}. In a more physiological model of NASH, NRF2-deficient mice fed a high-fat diet also developed exacerbated hepatic steatosis and inflammation suggesting the need for NRF2 to suppress the onset of these symptoms\textsuperscript{118,132}. Furthermore, pharmacologic activation of NRF2 by the tricyclic cyanoenone TBE-31 in wild-type, but not NRF2-knockout mice, which had been rendered obese and insulin resistant by chronic consumption of high-fat and high-fructose diet, reversed insulin resistance, suppressed hepatic steatosis, and ameliorated both NASH and liver fibrosis\textsuperscript{122}. Pharmacological activation of NRF2 by TBE-31 antagonizes SREBP-1c and ChREBP and expression of their lipid-biosynthetic target genes, which likely involves activation of AMPK\textsuperscript{122,133}. Moreover, in mouse liver, genetic activation of NRF2 antagonizes expression of the gluconeogenic enzymes PEPCK and G6PC, which may also involve AMPK\textsuperscript{133}. In liver biopsies of NASH patients, pathological ROS levels were found together with an increased NRF2-gene signature, suggesting an attempt to reduce the oxidant and inflammatory burden\textsuperscript{134}.

\textit{Cardiovascular disease}

An imbalance between the production and disposal of ROS resulting in an excessive formation of damaging oxidative species has been postulated to play a role in a number of cardiovascular diseases, such as hypertension, atherosclerosis, diabetic vascular disease,
myocardial ischemia-reperfusion injury and heart failure\textsuperscript{135}. In addition, low grade, persistent inflammation within the vascular wall is characteristic of the atherogenic process and development of vulnerable atherosclerotic plaques that are prone to rupture, subsequently leading to thrombosis and end-organ ischemia. Given that NRF2 is the key regulator of antioxidant defense and also has direct anti-inflammatory properties, it is logical to assume that NRF2 would protect against ROS-related cardiovascular disease. Indeed, NRF2 activating agents, including fumarate and hydrogen sulfide, have shown protective effects in many animal models of cardiovascular disease, such as cardiac ischemia-reperfusion injury\textsuperscript{136,137} and heart failure\textsuperscript{138,139}. The role of NRF2 in atherosclerosis in mouse models of hypercholesterolemia is less straightforward: the loss of NRF2 in bone marrow derived cells aggravates atherosclerosis\textsuperscript{140,141}, whereas global deficiency of NRF2 alleviates atherosclerosis assessed by the extent of lesion development\textsuperscript{142-145}, yet increases plaque inflammation and vulnerability\textsuperscript{145}. Nevertheless, several NRF2 activating agents have been shown to be atheroprotective in a variety of animal models of atherosclerosis\textsuperscript{146-148}. Cardiac diseases caused by mutations in contractile, cytoskeletal proteins and molecular chaperones can account for about 30\% of inheritable cardiomyopathies\textsuperscript{149}. In some of these settings, reductive rather than oxidative stress, coupled with protein aggregation, is associated with the cardiomyopathies. Recently, systemic inflammation and pathological ROS formation in hemodialysis patients were associated with down-regulation of NRF2\textsuperscript{150} and a polymorphism located in the \textit{NFE2L2} promoter has been associated with increased mortality in these patients\textsuperscript{151}. Disruption of the NRF2 signaling axis prevents reductive stress and delays proteotoxic cardiac disease in mice overexpressing human CRYAB (\(\alpha\)-crystalline B chain), a molecular chaperone, in the
Thus, as highlighted throughout this review, the context for targeting NRF2 is very important – more may not always be better.

**Neurodegenerative disease**

In various forms of neurodegenerative disease, the connection between NRF2 and proteostasis is particularly pertinent since these diseases are characterized by abnormal protein aggregation\(^43\). Compelling evidence for a protective role of NRF2 in proteinopathy has been provided in Alzheimer’s disease (AD) models of amyloidopathy\(^{153,154}\), tauopathy\(^{155}\) or both\(^{40,156,157}\) and in Parkinson’s disease (PD) models of alpha-synucleinopathy\(^{158-160}\). In humans, APP and TAU injured neurons express increased levels of NRF2 and its target p62\(^{40,161}\). These findings are consistent with the recently reported role of NRF2 in upregulating expression of genes involved in macroautophagy\(^40\) and chaperone mediated autophagy\(^{39}\), two essential mechanisms for clearance of APP, TAU and \(\alpha\)-synuclein. Upregulation of NRF2 protected neurons against the toxicity of mutant \(\alpha\)-synuclein and leucine-rich repeat kinase 2 (LRRK2)\(^{162}\), which also leads to neurodegeneration associated with accumulation of misfolded proteins\(^{163}\). Curiously, whereas NRF2 activation increased the degradation of \(\alpha\)-synuclein, misfolded diffuse LRRK2 was sequestered into inclusion bodies.

The role of NRF2 in astrocytes and microglia is expected to be especially relevant as they show the highest expression levels in the brain (**Figure 2B**). Using transgenic mice with an ARE-driven alkaline phosphatase reporter gene, it was found that astrocytes are highly responsive to NRF2 activation in several models of neurodegeneration\(^{164}\), pointing to the relevance of NRF2 in the nurturing effect of astrocytes by providing metabolic and GSH precursors to endangered neurons\(^{46,165}\). Microglia, as the immune response cell of the
brain, is also crucial in NRF2 mediated responses\textsuperscript{166,167}. In the murine model of PD based on intoxication with the Parkinsonian toxin methyl-4-phenyl-1,2,3,6-tetrahydropyridine, it was reported that NRF2 modulates microglial dynamics, and thereby reduces production of COX-2, NOS2, IL-6, and TNF-\(\alpha\) and increases the levels of several anti-inflammatory markers\textsuperscript{55,168}. The activation of microglia by TAU-injured neurons appears to be related, at least in part, to the crosstalk through the chemokine fractalkine. Both in mice and in humans, TAU-injured neurons release fractalkine, which in neighboring microglia inhibits GSK-3 and leads to increases in NRF2 protein. In turn, NRF2 reduces the release of TNF-\(\alpha\) and IL-6 and participates in the reprogramming of microglia towards a wound healing response\textsuperscript{161}.

Several NRF2-target genes including \textit{HMOX1}, \textit{NQO1}, \textit{GCLM} and p62/SQSTM1 are upregulated in AD and PD brains\textsuperscript{159,160-171}. The relevance of this upregulation is demonstrated by genetic analyses of the association between disease risk and the functional haplotype made of three SNPs in the \textit{NFE2L2} promoter. In ALS, a protective haplotype allele was associated with a 4-year delay in disease onset\textsuperscript{172}, but another study did not find a clear association\textsuperscript{173}. In AD, another haplotype variant was associated with a 2-years earlier onset of disease\textsuperscript{76}. More detailed evidence has been reported for PD. Initially, a protective haplotype was associated with delayed onset of disease in a Swedish cohort and reduced risk in a Polish cohort of PD patients\textsuperscript{77}. Afterwards, these findings were replicated in four independent European case-control studies\textsuperscript{174}, but not in a Taiwanese population\textsuperscript{175}, suggesting differences in ethnicities and environmental factors.

Pharmacological activation of NRF2 also holds promise for the treatment of Huntington’s disease (HD) and Friedreich's ataxia (FRDA), where oxidative stress and inflammation are important drivers of pathology. Studies in mice, model organisms and
cultured cells from patients with HD and FRDA have reported impaired NRF2 signaling\textsuperscript{53,176-178}, and the beneficial effects of pharmacological NRF2 activators. Thus, activation of NRF2 by triazole derivatives suppressed the release of pro-inflammatory cytokines in primary mouse HD microglia and astrocytes and in cultured monocytes from HD patients\textsuperscript{53}, and was neuroprotective in \textit{ex vivo} HD rat corticostriatal brain slices and an HD Drosophila model\textsuperscript{179}. In mouse models of HD, DMF and the triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improved the brain pathology and behavior of the animals\textsuperscript{180,181}. Treatment with sulforaphane and the cyclic cyanoenones TBE-31 or RTA-408 led to improved mitochondrial function and protection against oxidative stress in fibroblasts and cerebellar granule neurons from FRDA mouse models, and in fibroblasts from HD patients\textsuperscript{182,183}. Altogether, the available evidence suggests that a modest activation of NRF2 is neuroprotective in the brain.

**The NRF2/KEAP1 axis and cancer**

NRF2 has been reported to exert both anti- and pro-tumorigenic actions. Here we provide a brief summary of the current understanding of the role of NRF2 in cancer and refer the reader to a recent comprehensive review discussing NRF2 in the context of the hallmarks of cancer\textsuperscript{12}.

In non-malignant cells, NRF2 activation affords resistance to oxidant-induced genetic damage and chemical and physical carcinogens due to enhanced defenses that include antioxidant\textsuperscript{184} and radioprotective\textsuperscript{114} activities, as well as accelerated biotransformation and clearance of DNA-damaging agents\textsuperscript{185}. Moreover, activation of the NRF2 transcriptional response appears to maintain ROS levels below those necessary for signaling to proteins critical for tumorigenesis, such as phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K), mitogen activated kinases, hypoxia inducible factor-1 and NF-κB\textsuperscript{186}.

On the contrary, in the early stages of tumor development, cancer cells with constitutive activation of NRF2 are selected as a means of enabling adaptation to a hostile microenvironment, chemotherapy, radiotherapy or high endogenous ROS levels. Additionally, in rapidly proliferating cells, NRF2 supports intermediary metabolism by enhancing the biosynthesis of nucleotides\textsuperscript{26} and amino acids\textsuperscript{187}, but also generates metabolic imbalance and dependence on glutaminolysis, which could be therapeutically exploited\textsuperscript{188,189}.

Somatic loss-of-function mutations in KEAP1 or gain-of-function mutations in NFE2L2 are common in non-small cell lung cancer and some other cancers in which environmental factors are important etiological components\textsuperscript{190}. A comprehensive catalogue of NRF2 mutations in The Cancer Genome Atlas (TCGA) database identified 226 unique NRF2-mutant tumors within 10,364 cases, with gain-of-function NRF2 mutations occurring in 21 out of 33 tumor types\textsuperscript{191}. The frequent occurrence of such mutations suggests a potential benefit of NRF2 inhibitors in cancer treatment, triggering a search for NRF2 inhibitors (Box 1). This is a completely open field for pharmacology and at this time is at the level of proof-of-concept research. Alternative approaches for NRF2 suppression include targeting proteins that confer dependence on NRF2 and/or are selectively expressed in KEAP1-mutant cancer cells. Examples include inhibitors of glutaminase\textsuperscript{188,189} and NR0B1, an atypical orphan nuclear receptor that participates in a multimeric protein complex to regulate transcription in KEAP1-mutant cells\textsuperscript{192}. It should be noted however that no evidence exists to date that either KEAP1 or NFE2L2 mutation alone can instigate malignant transformation, but co-occurrence with oncogenic drivers seems necessary; PI3K
kinase pathway alterations having the strongest association\textsuperscript{193}. Most tellingly, the hypomorphic “\textit{Keap1}-knockdown” mouse in which NRF2 is globally upregulated does not spontaneously develop tumours\textsuperscript{194,195}, whereas the simultaneous deletion of \textit{Keap1} and \textit{Pten} in the murine lung promotes adenocarcinoma formation\textsuperscript{195}. Importantly, the resulting tumors are characterized by an immunosuppressive microenvironment, which can be therapeutically exploited by use of immune checkpoint inhibitors\textsuperscript{195}.

It is clear that the context within which NRF2 is genetically activated is important in terms of tumorigenesis, as oncogene (K-Ras\textsuperscript{G12D}) activation of NRF2 signaling in rodents can enhance tumor development\textsuperscript{196} whereas genetic knockdown of \textit{Keap1} (also leading to activation of NRF2 signaling) strongly blunts Notch1-driven tumorigenesis\textsuperscript{197} as well as UV radiation-mediated cutaneous carcinogenesis\textsuperscript{51,198}. Notably, in the latter model, the protective effect of KEAP1 knockdown against initiation of cutaneous carcinogenesis is abrogated by the simultaneous loss of NRF2\textsuperscript{199}. This dichotomous role of NRF2 is supported by extensive experimental evidence in which its activation enhances antitumor immunity to prevent lung carcinogenesis, but only after tumor initiation accelerates malignant growth\textsuperscript{200}. Also, \textit{Nrf2}-knockout mice submitted to chemically-induced carcinogenesis exhibit an increased number of tumors (enhanced initiation) but of much smaller size (impaired progression) compared to wild-type littermates\textsuperscript{201}. Hence, low NRF2 activity facilitates initiation of carcinogenesis, whereas persistent constitutively high NRF2 activity can drive cancer progression and resistance to therapy\textsuperscript{202}.

\textbf{NRF2 modulators in clinical development}

\textit{Fumaric acid esters}
Fumaric acid esters represent a group of NRF2 activators upon which industry is focusing huge effort. The most clinically successful example is DMF (compound 1, Figure 3A), which was approved in 1994 for the treatment of psoriasis and, based on its efficacy in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis\textsuperscript{203}, was repurposed in 2014 by Biogen (Tecfidera) for the treatment of relapsing-remitting multiple sclerosis. Early studies in rodents preceding the discovery of NRF2 had reported that DMF is a robust inducer of the NRF2-transcriptional targets GST and NQO1\textsuperscript{204}, and it was later shown that the DMF metabolite monomethyl fumarate (MMF, compound 2, Figure 3A) reacts with C151 in KEAP1, thereby activating NRF2\textsuperscript{203}. Safety has been a priority since the discovery of the inducer activity of DMF, and it was noted that the concentrations of DMF required to obtaining significant enzyme inductions were well tolerated by rodents\textsuperscript{204}. DMF exhibited a favorable safety and tolerability profile in two phase 3 trials\textsuperscript{205,206}, and after its commercialization it has become one of the most successful new medicines in recent years. However, a drawback of Tecfidera is the occurrence of mild to moderate abdominal pain, flushing, diarrhea and nausea. While these adverse effects can be managed, a more serious symptom is the occurrence of leukopenia in patients with low leukocyte counts at the beginning of treatment. In fact, animals treated with DMF had much lower levels of granulocytes in their nervous system than those that did not receive the drug\textsuperscript{207}. This effect is not related to NRF2 but is most likely due to activation of the hydroxycarboxylic acid receptor since mice lacking this protein had high levels of granulocytes regardless of whether they were treated with DMF\textsuperscript{207}. These observations highlight the importance of carefully selecting the inclusion criteria for treatment.

As mentioned above, DMF is metabolized \textit{in vivo} to MMF, which inactivates KEAP1 through adduct formation at C151\textsuperscript{203}. Because of this metabolic conversion, several
Biopharmaceutical companies are now developing compounds with slow and sustained release of MMF that would show improved bioavailability and fewer side effects compared to DMF (Table 1). Alkermes (acquired by Biogen) has developed diroximel fumarate (ALK8700/BII089, compound 3, Figure 3A), an MMF prodrug with reduced gastrointestinal side effects that is now in a phase 3 clinical trial for multiple sclerosis (NCT03093324). XenoPort (acquired by Arbor Pharmaceuticals) has developed tepilamide fumarate, an MMF prodrug (XP23829, compound 4, Figure 3A). Compared to DMF, XP23829 has higher solubility and permeability, greater absorption following oral administration, improved efficacy and reduced gastrointestinal side effects in preclinical models, and is now in a phase 2 clinical trial for plaque psoriasis (NCT02173301). Catabasis is developing another chemically-linked conjugate of MMF and docosahexaenoic acid (CAT4001) with potential for enhanced cell targeting, efficacy, improved safety and tolerability compared to the effect of separate bioactive molecules. Specific enzymes release the two components inside the cell, where they simultaneously modulate multiple biological targets, including NRF2 and NFκB in cells and animal models, and show promise for the treatment of neurodegenerative diseases, such as FRDA and amyotrophic lateral sclerosis (ALS). A similar technology is being developed by V ClinBio Inc. in their conjugates of MMF and eicosapentaenoic acid (VCB101, compound 5, Figure 3A and VCB102) for the treatment of multiple sclerosis and psoriasis (Table 1).

Sulforaphane
A widely used naturally-occurring electrophilic activator of NRF2 is sulforaphane (SFN, 4-methylsulfinylbutyl isothiocyanate, compound 6, Figure 3A). This compound was initially isolated by Paul Talalay and Yuesheng Zhang as the principal inducer of the NRF2-target
enzyme NQO1 from extracts of *Brassicaceae* plants\(^{208}\), and interacts with C151 of KEAP1\(^{14,209}\). Notably, SFN goes through the blood-brain barrier\(^5\) and has protective effects in numerous preclinical models of neurological conditions\(^{210}\). In a double-blind placebo-controlled clinical trial in young men with autism spectrum disorder, orally administered capsules of SFN-rich broccoli sprout extracts have shown significant improvement in behavioral measures as assessed by Aberrant Behavior Checklist and Social Responsiveness Scale; the total scores on these scales reversed toward pretreatment levels upon cessation of treatment\(^{211}\). Three-day-old broccoli sprouts are rich in glucoraphanin, a precursor molecule that is hydrolyzed by the plant enzyme myrosinase to release SFN and glucose\(^{212}\). A similar \(\beta\)-thioglucosidase enzyme is present in the gut microbiota and therefore, the actual levels of released SFN are highly dependent on dietary habits and microbiome composition, are affected by antibiotic treatments\(^{213}\) and display circadian rhythmicity\(^{214}\). Nevertheless, either as sprout extract or highly purified SFN, more than 500 subjects have received over 25,000 doses, demonstrating a high safety profile. There are over 20 currently ongoing clinical trials.

Considering issues related to intellectual property surrounding a natural compound, the fact that SFN is unstable at room temperature, and the need to accurately control dosing, Evgen Pharma has developed a pharmaceutical form of SFN, SFX-01 (compound 7, **Figure 3A**). SFX-01 is chemically synthesized SFN encapsulated in cyclodextrin to create a stable, solid-form pill or capsule with excellent bioavailability. SFX-01 is now being studied in clinical trials of subarachnoid hemorrhage (NCT02614742) and metastatic breast cancer (NCT02970682) (**Table 1**). Evgen also has a series of novel SFN-based analogs that are in preclinical evaluation. In addition, a number of nutraceutical companies
are producing preparations that contain NRF2 inducers, including SFN, with various
degrees of standardization. One example is Prostaphane®, from the Nutrinov Laboratory,
which is a stabilized free SFN, extracted from broccoli seeds with demonstrated benefits in
managing biochemical recurrences after radical prostatectomy in a placebo-controlled
clinical trial of prostate cancer. The bioavailability and potency of both SFX-01 and
Prostaphane® are equivalent to those of the much less stable SFN. Another example is
the encapsulated dietary supplement Avmacol (Nutramax Laboratories), which contains
glucoraphanin from finely-milled broccoli seeds together with freeze-dried broccoli sprout
powder to provide myrosinase. This supplement is currently in use in clinical trials to
modulate disease symptoms and/or biomarkers related to autism spectrum disorder,
schizophrenia and environmental pollution.

**Cyanoenone triterpenoids**

Accumulating evidence suggests that fumaric acid esters, SFN and other small electrophiles
that bind covalently to KEAP1 may benefit from a larger scaffold structure to confer better
selectivity (and likely potency) and more controllable pharmacokinetic/pharmacodynamic
properties. The development of pentacyclic Michael acceptor-bearing cyanoenone
triterpenoids may fulfill these requirements. Initially developed by Michael Sporn, Gordon
Gribble and Tadashi Honda from the natural product oleanolic acid, these pentacyclic
triterpenoids are the most potent NRF2 activators known to date, are sensed by C151 in
KEAP1, and are now under clinical development by Reata Pharmaceuticals and Kyowa
Hakko Kirin Co., Ltd..

Two clinically advanced compounds, bardoxolone methyl (BARD) (compound 8, Figure 3A) and omaveloxolone (compound 9, Figure 3A), normalize metabolism, increase
mitochondrial energy production, boost cellular antioxidant capacity and lower ROS levels\textsuperscript{221} (Table 1). In preclinical studies, BARD or analogs have been shown to improve kidney function by reducing inflammation, fibrosis and oxidative stress and increasing the filtration surface area in the glomerulus\textsuperscript{222,223}. With a modification of the selection criteria to exclude patients with signs of incipient heart failure (elevated B-type natriuretic peptide), BARD is now being tested in clinical trials for several rare conditions that are associated with chronic kidney disease, most of which have no approved treatments: these include Alport syndrome (NCT03019185), autosomal dominant polycystic kidney disease, IgA nephropathy, type 1 diabetes and focal segmental glomerulosclerosis (NCT03366337), in which pro-inflammatory and pro-fibrotic processes contribute to glomerulosclerosis and impaired kidney function\textsuperscript{224}. BARD treatment has the potential to delay or prevent the decline in glomerular filtration rate that results in the need for dialysis or transplant in patients with Alport syndrome and other rare forms of chronic kidney disease (CKD). Thus, in a phase 2 clinical trial in patients with type 2 diabetes and CKD (NCT02316821), BARD treatment led to statistically significant increases in directly-measured glomerular filtration rate, and upon exclusion of patients at risk of fluid retention, was well tolerated. Based on these results, Kyowa Hakko Kirin has initiated a phase 3 clinical trial (NCT03550443) in diabetic patients with stage G3 or G4 CKD, with the support of the Japanese SAKIGAKE Designation system.

In addition, BARD is being studied in patients with pulmonary arterial hypertension (NCT03068130) and pulmonary arterial hypertension due to connective tissue disease with pulmonary arterial hypertension (CTD-PAH) (NCT02657356), which is a serious and progressive disease that leads to heart failure and death. The difference between CTD-PAH and idiopathic etiologies is largely attributed to the complex interplay between
inflammation, autoimmunity, and systemic vasculopathy that contribute to the pathogenesis of connective tissue disease. CTD-PAH patients have increased inflammatory processes due to upregulation of NF-κB\textsuperscript{225}, are less responsive to existing vasodilator therapies than patients with the idiopathic PAH, and have a worse prognosis\textsuperscript{226}. BARD was tested in CTD-PAH patients in a phase 2 study and is currently being tested in phase 3. Omaveloxolone is currently being tested in a registrational phase 2 clinical trial for patients with FRDA (NCT02255435), a genetic neuromuscular disorder in which NRF2 is downregulated\textsuperscript{176-178}. Of note, there are no currently approved therapies for the treatment of FRDA\textsuperscript{227} (Table 1).

**Nitro fatty acids**

Nitrated derivatives of fatty acids (NO\textsubscript{2}-FA) are endogenous signaling mediators with anti-inflammatory and anti-fibrotic activities in preclinical animal models of metabolic and inflammatory disease\textsuperscript{228}. The nitroalkene group confers electrophilicity to their β-carbon, promoting the rapid formation of reversible NO\textsubscript{2}-FA Michael adducts with nucleophiles, such as cysteines, a modification termed nitroalkylation\textsuperscript{229,230}. It has been shown that nitro oleic acid (NO\textsubscript{2}-OA, 9-nitro-octadec-9-enoic acid) reacts with cysteines in KEAP1, including C273 and C288, thereby activating NRF2\textsuperscript{231,232}. The reversibility of this reaction\textsuperscript{229,230,233} prevents the possibility for accumulation of stable NO\textsubscript{2}-FA thiol adducts, which could lead to cytotoxicity. Indeed, phase 1 safety evaluation has demonstrated that the lead compound, CXA10 (10-NO\textsubscript{2}-OA, 10-nitro-octadec-9-enoic acid, a specific regioisomer of NO\textsubscript{2}-OA) (compound 10, Figure 3A) is safe in humans at pharmacologically active doses\textsuperscript{234}. CXA10 is currently being developed by Complexa Inc.
as a treatment for focal segmental glomerulosclerosis and pulmonary arterial hypertension²³⁴ (Table 1). The synthesis and biological evaluation of nitroalkenes derived from α-tocopherol was also recently reported²³⁵.

**Hydroxylamine**

A special challenge is to deliver NRF2 activators that can pass the blood-brain barrier. The route of administration (injection, oral, topical) is also crucial for specific diseases. Othera Pharmaceuticals (now acquired by Colby Pharmaceutical Co.) is developing a di-substituted hydroxylamine with antioxidant properties (OT551) for topical use that inhibits oxidative stress and disease-associated inflammation by targeting KEAP1 (compound 11, Figure 3A). In preclinical studies, an ophthalmic solution of this compound protected the retinal pigment epithelium and photoreceptors from oxidative damage and inflammation, and a phase 2 trial on age-related macular degeneration has demonstrated efficacy in preventing the progression of vision loss (NCT00485394) (Table 1).

**TFM735**

A high-throughput screening reporter strategy assessing the stability of a chimeric protein comprising the NRF2 N-terminal domain fused to LacZ (NRF2d-LacZ)²³⁶ identified TFM735 as a lead compound (compound 12, Figure 3A). TFM735 activates NRF2 in a C151-dependent manner, inhibits the synthesis of IL-6 and IL-17 from stimulated human peripheral blood mononuclear cells, and the progression of experimental autoimmune encephalomyelitis in mice²³⁷. This compound is currently in preclinical development by Mochida Pharmaceuticals for the treatment of multiple sclerosis (Table 1).
**NRF2/KEAP1 protein-protein interaction inhibitors**

Recent attention has focused on the development of non-electrophilic non-covalent compounds that interfere with the direct protein-protein interaction (PPI) between KEAP1 and NRF2, or the PPI between KEAP1 and Cul3. By interfering directly with the interaction between KEAP1 and NRF2 or Cul3, the compounds do not require a covalent binding component to their mode of action. There are potential advantages to this approach, including the scope to explore new chemotypes of NRF2 inducers, different pharmacodynamics due to a different mode of interaction with KEAP1 and different off-target effect profiles due to a cysteine-independent binding mechanism. There is evidence that electrophilic and non-electrophilic (PPI) KEAP1 inhibitors differ in their spectrum of biological effects, an example being the ability of non-electrophiles to induce mitophagy in contrast to electrophiles such as SFN and DMF; this points towards potential differences in pharmacological activity and therapeutic utility between the two compound classes.

The design of PPI inhibitors has been guided by the availability of the crystal structure of the Kelch domain of KEAP1 (Figure 3B). Several types of PPI inhibitors have been reported; the major chemical classes developed with input from the pharmaceutical industry are shown in Figure 3B. The naphthalene bis-sulfonamide compounds originated from a high-throughput screening campaign at Biogen and subsequently elaborated by Jiang et al. at China Pharmaceutical University to provide compound 13 (CPUY192018) and analogues. This bis-carboxylic acid compound is a high-affinity ligand for KEAP1, which induced the expression of ARE-dependent genes at low micromolar concentrations. Astex and GlaxoSmithKline also identified sulfonamide-containing lead compounds from an x-ray crystallography fragment-based screening program. The lead compounds in this case are exemplified by compound 14, a low
nanomolar inhibitor of the KEAP1-NRF2 PPI that increased the expression of the NRF2-target gene $NQO1$ in treated COPD patient-derived epithelial cells. The compound was capable of reducing lung inflammation in rats after $i.v.$ administration and effectively suppressed ozone-induced accumulation of leukocytes in bronchoalveolar fluid and restored GSH concentrations$^{246}$. Compounds from this series have shown efficacy in several animal models of oxidative stress that simulate features of pulmonary disease and are currently being developed for clinical evaluation. Two further classes of mono-acidic PPI inhibitors have been developed which are not sulfonamides. The first class, developed at Rutgers by Hu et al.$^{247}$ and elaborated by Evotec and UCB Pharma$^{248}$, were the tetrahydroisoquinolines, e.g. compound 15, which were low micromolar inhibitors of the KEAP1-NRF2 PPI. The second class was developed by Toray Industries and RIKEN and incorporated an oxadiazole motif; compound 16 is an inhibitor of the PPI with binding activity in the micromolar range$^{249}$. The highlighted compounds or their analogues have been co-crystallised with the KEAP1 Kelch domain; Figure 3B illustrates the occupancy of the binding site sub-pockets that compounds 13-16 achieve and provide insights into how these ligands may be refined in the future.

New PPI inhibitors are also being developed by C4X Discovery using a combination of computational chemistry, ligand nuclear magnetic resonance (NMR) spectroscopy and protein crystallography approaches and by Keapstone, using a structure-based drug design approach. Academic groups are also contributing to the pool of non-electrophilic NRF2 inducers$^{250,251}$.

A significant challenge remains in making PPI inhibitors that possess suitable drug metabolism and pharmacokinetic properties for use in both peripheral and central nervous system applications, the latter being an area in which KEAP1 inducers with a strong safety
profile are required for chronic administration for conditions such as AD and PD. At this time, the potential advantage of improved target selectivity of the non-electrophilic PPI inhibitors is offset by the relatively high molecular weights of the current compounds, a requirement for blocking the large KEAP1-NRF2 interface, and the need for polar functional groups to confer tight KEAP1-binding affinity. Thus, many of the prototype compounds that were identified by in vitro studies, at present exhibit poor absorption, distribution, metabolism and excretion properties. For instance, the naphthalene bis-sulfonamide 13 protects against dextran sodium sulfate (DSS)-induced colitis in mice, activates NQO1 expression in cultured NCM460 cells in the low micromolar range, and binds KEAP1 in vitro, demonstrating the offset between protein binding and biological activities.

The majority of the in vivo evaluations of PPI inhibitors have focused on peripheral inflammatory conditions. For example, the compound NK-252 (an analogue of 16) was identified by Toray Industries as a relatively weak KEAP1 inhibitor, but had a protective effect against H$_2$O$_2$-induced cytotoxicity and reduced the fibrosis score in rats fed with a choline-deficient L-amino acid-defined diet, a model system for NASH.

**Targeting NRF2 with KEAP1-independent drugs**

Increasing evidence indicates that NRF2 exhibits multiple layers of regulation in addition to that exerted by KEAP1, such as transcriptional\textsuperscript{196}, epigenetic\textsuperscript{254,255}, covalent protein modification\textsuperscript{256,257}, proteasome degradation in KEAP1-independent manner\textsuperscript{258-261}, and regulation of NRF2-dimerizing partners that target binding to ARE sequences\textsuperscript{262,263}. At the level of pharmacological development, a KEAP1-independent mechanism of ARE-mediated gene regulation involves modulation of the transcriptional repressor BACH1 (i.e.,
broad complex, tramtrack and bric à brac and cap’n’collar homology 1), which inhibits the transactivation of a subset of NRF2-regulated genes and more specifically HMOX1. VTV Therapeutics is now analyzing if this subset is sufficient to elicit therapeutic benefits. They have developed a novel class of non-electrophilic small molecules that inhibit BACH1 binding to some ARE-driven genes independently of KEAP1.

**Challenges and considerations**

**Pharmacodynamics assessment**

Considering that NRF2 has a very short half-life, even after drug-induced stabilization, the most appropriate dosing regimen for a therapeutic benefit needs to be inferred by indirect indicators of its activation in the diseased organs. One possibility is to analyze drug distribution and NRF2 gene expression signatures in accessible cells or tissues (such as peripheral blood mononuclear cells, nasal lavage fluid cells, exfoliated bladder cells, buccal cells and skin) with the hope that the transcriptomic signature of NRF2 in these cells reflects local engagement in other tissues (such as the lung, liver, and brain). In the case of communities unavoidably exposed to harmful environmental chemicals, the urinary levels of their corresponding metabolites have been used as biomarkers of pharmacodynamic action mediated through NRF2.

Activation of the NRF2 pathway is characterized by a time-, tissue-, dose-, onset-, and duration-dependent differential gene expression. **Table 2** shows the half-lives of a representative subset of NRF2-regulated gene products. As many of these proteins have a relatively long half-life, their biochemical activities are expected to last much longer than the time interval over which NRF2 is stabilized or the presence of its pharmacological activator, the latter of which is often cleared within several hours. As such, the
pharmacodynamics of NRF2-activating molecules are observed over much longer periods of time than the levels of NRF2, and do not correspond to the plasma drug concentrations. Thus, the NRF2 activator TBE-31, a tricyclic cyanoenone closely related to the triterpenoids described above, has a half-life of 10 h in murine skin and plasma\textsuperscript{51,270}, whereas NRF2-dependent induction of NQO1 protein is still evident in the skin of the animals three days after the last dose of topically-applied drug\textsuperscript{51}. Based on the fact that NRF2 activators lead to the “stimulation of the production or inhibition of factors which control the measured effect”, an “indirect pharmacodynamic response” model\textsuperscript{271,272} may be a more logical approach for testing the NRF2 activator pharmacodynamics towards clinical applications.

The concentration and distribution of NRF2-activating drugs in the relevant tissue, as well as their solubility, cell permeability, metabolic stability, and protein binding, will also play a major role in the extent of NRF2 activation, ultimately leading to the desired long-lasting pharmacodynamic effects. Therefore, optimization of clinically meaningful drug exposure requires an analysis of dose-dependent gene regulation by a putative NRF2 activator. Furthermore, NRF2 target engagement studies must consider patient age and performance status, as the ability of drugs to activate NRF2 or promote an “adaptive response” appears to be reduced in older and less healthy subjects. This was recently seen in a clinical trial of DMF in patients with relapsing-remitting multiple sclerosis, where it was found that the degree of induction of the NRF2 transcriptional target NQO1 negatively correlated with patient age, and that patients with higher NQO1 protein levels at 4-6 weeks after the start of therapy were more likely to show no evidence of disease activity during the following year\textsuperscript{267}. 
**Drug selectivity**

The identification of highly reactive cysteines in KEAP1 was crucial for the understanding of the mechanism by which electrophilic compounds interact covalently with this ubiquitin ligase substrate adaptor. Structural information suggests that certain drugs acting on C151 may disrupt the interaction with Cullin-3 (Cul3)/Rbx1\textsuperscript{273,274}, thus leaving the KEAP1 pool saturated with bound NRF2 and allowing newly synthesized NRF2 to evade degradation: this was demonstrated using the model electrophile \textit{N}-idoacetyl-\textit{N}-biotinylhexylenediamine\textsuperscript{275}. Other compounds may modify KEAP1 in a way that it is no longer capable of interacting with NRF2 at both the high- and low-affinity sites within the transcription factor. Notably, some electrophilic NRF2 activators, such as the cyclic cyanoenones bind to thiols covalently but do not form irreversible adducts\textsuperscript{276,277}. Consequently, they combine the desirable features of both irreversible covalent drugs (i.e., high potency and sustained target engagement), as well as that of reversible non-covalent drugs (i.e., absence of permanent modification and therefore possible destruction or immunogenicity of their protein targets)\textsuperscript{278}. A potential drawback of such molecules is that they might react with redox-sensitive cysteines in proteins other than KEAP1, hence compromising their function. The issue of specificity of thiol-reactive molecules indicates that the window that allows for therapeutically relevant KEAP1 modification in the absence of thiol modifications within other proteins needs to be determined for each compound (Figure 1B). Such a hierarchical presentation of target cysteines within KEAP1 as well as other thiol-containing non-target proteins has been termed the “cysteine code”\textsuperscript{279} and is influenced by both the chemistry and dose of inducer\textsuperscript{280}.

A significant potential advantage of KEAP1-NRF2 PPI inhibitors is improved target selectivity. However, off-target effects cannot be completely excluded \textit{a priori} for any
small molecule. In addition, KEAP1 targets proteins other than NRF2\textsuperscript{281} for ubiquitination, and these might also be affected. One of the few types of PPI inhibitors for which off-target selectivity has been evaluated are the potent mono acidic sulfonamides, for example, compound \textbf{10} appeared to be relatively selective for KEAP1, showing modest activity in a GlaxoSmithKline enhanced cross-screen panel of \textit{in vitro} assays to identify potential off-target effects\textsuperscript{246}.

\textit{Animal models}

A problem that precludes successful drug development for most chronic diseases is the incomplete reproducibility of human pathologies in animal models\textsuperscript{282}. This issue may be associated with the lack of a very important hallmark of human degenerative diseases, namely the progressive loss of homeostatic functions associated with NRF2. In fact, although much work still needs to be done in humans, evidence from animal studies indicates that NRF2 activity declines with aging and that the pharmacological or genetic up-regulation of NRF2 increases life-span and improves health-span\textsuperscript{283,284}. The lack of an “NRF2 variable” in animal models of chronic diseases is well exemplified in murine models of AD. The current models are based on the assumption that expression of toxic APP or TAU mutant proteins in an otherwise healthy animal background replicates the human pathology. While these models provide valuable information about the onset and progression of the proteinopathy, they have systematically failed to translate therapeutic success to humans. The reasons for this failure may be related to the fact that these models do not consider the disease-related decline of homeostatic functions such as those related to NRF2. More sophisticated preclinical models will require a reverse translational approach in which not only the anatomopathological features of a specific disease are replicated in
animals, but also the compromised redox, inflammatory or protein homeostasis. Thus, the NRF2-knockout mouse shares many alterations common to AD patients or even aged individuals\textsuperscript{156}. Recent studies have demonstrated that compared to wild-type animals, NRF2-knockout mice fed high-fat diet display greater neurovascular dysfunction, blood-brain barrier disruption, neuroinflammation, amyloidogenic gene expression, and cognitive decline, mimicking many of the phenotypic changes that occur with aging\textsuperscript{285}. The introduction of low NRF2 expression as a variable to reduce homeostatic responses may be useful to improve current models of chronic diseases towards better therapeutic outcomes. Considering the slow decline of NRF2 activity with aging, the heterozygous $Nrf2^{+/−}$ mouse might be a suitable model to replicate both reduced basal expression and pharmacological upregulation.

\textbf{Cancer risk}

From a pharmacological point of view, it is necessary to determine how significant is the risk posed by increasing NRF2 levels beyond a safe threshold of causing cancer (\textbf{Figure 4}). The impact of somatic mutations that promote NRF2 stability in cancer cells is markedly different to that caused by pharmacologic activation of NRF2. Thus, somatic mutations in $KEAPI$ and $NFE2L2$ result in high, unrestrained NRF2 activity which is entirely distinct from the pulsatile activation caused by pharmacologic administration of NRF2 activators. Kinetic features such as amplitude and areas under the curve, reflecting intensity and duration of NRF2 signaling, are vastly different in settings of activation by genetic versus pharmacological means\textsuperscript{202,286}. Moreover, gene loss or inactivating mutations in $KEAPI$ do not appear to have the same effect as pharmacological inhibition of this protein. Thus, KEAP1 loss increased the levels of NRF2 but also several oncogenic targets of this E3
ligase adapter, including inhibitor of NF-κB kinase subunit beta (IKKβ) and B-cell lymphoma 2 (BCL2) that might be at least partially responsible for malignant transformation. Accordingly, in a panel of cell lines with functional KEAP1, a well-established NRF2 activator, the BARD analog RTA-405, increased NRF2 but not IKKβ or BCL2 levels, and did not confer a growth or survival advantage to tumor cells.\(^{287}\)

While at the present time a cancer risk from NRF2 activators cannot be dismissed, it is encouraging to see that a meta-analysis of a phase 3 trial of DMF has shown no difference in the cancer rate between the placebo and DMF-treated groups.\(^{288}\) It is also important to note that some NRF2-activating drugs may reduce this risk if they have additional targets with antitumor effects. Thus, DMF was recently found to inhibit GAPDH\(^{289}\), and it is possible that such inhibition may lead to energetic crisis in highly glycolytic KRAS or BRAF mutant cancer cells thus preventing tumor development as shown for vitamin C.\(^{290}\)

**Outlook**

A hallmark of many chronic diseases is the loss of homeostatic responses such as redox signaling, metabolic flexibility, controlled inflammation and proteostasis. The multifactorial nature of these complex diseases could be targeted with one single hit at the transcription factor NRF2 as its activation elicits beneficial comprehensive, “multi-target” and long-lasting cytoprotective effects. Slowly but steadily biopharmaceutical companies are developing drugs that target KEAP1, the main regulator of NRF2 even though the peculiarity of the KEAP1/NRF2 system makes this approach particularly challenging for monitoring target engagement and off-target effects. In addition, the concern about an increased cancer risk needs to be definitively excluded. Over the next few years, the
ongoing clinical trials will undoubtedly provide significant advances in answering these questions.

**Box 1. Emergence of NRF2 inhibitors for cancer treatment**

Somatic mutations in the KEAP1/NRF2 axis have been found in several tumor types\(^{193}\), suggesting a potential benefit of NRF2 inhibitors in cancer treatment. Following ligand-mediated receptor activation and binding to the glucocorticoid response element, agonists of the glucocorticoid receptor, such as dexamethasone, inhibit the transcriptional activity of NRF2, at least on the *GSTA2* gene\(^{291}\). Agonists of the nuclear receptors retinoic acid receptor alpha (RAR\(\alpha\)) and retinoid X receptor alpha (RXR\(\alpha\)), including all-\(trans\)-retinoic acid, also inhibit the transcriptional activity of NRF2 in an ARE-reporter cell line and in the small intestine of mice fed a vitamin A-deficient diet\(^{292,293}\). It is likely that these mechanisms of regulation through nuclear receptors are not specific for NRF2, though RXR\(\alpha\) has been reported to interact directly with NRF2\(^{293}\).

Among pharmacological agents, brusatol, a quassinoid extracted from *Brucea javanica*, attracted initial attention as it reduced the expression of an ARE-luciferase reporter and sensitized a broad spectrum of cancer cells to cisplatin in culture and in xenografts\(^{294}\). However, it is now recognized that brusatol is a general inhibitor of protein synthesis, thus leading to the preferential inhibition of short-lived proteins, including but not limited to NRF2\(^{295,296}\). A similar concern was raised after the identification of the febrifugine derivative halofuginone in a high-throughput inhibitor screen in chemo- and radio-resistant cancer cells\(^{297}\). Halofuginone induced a cellular amino acid starvation response that repressed global protein synthesis and rapidly depleted NRF2 and other
proteins. The flavonoid luteolin was reported to accelerate the turnover of NRF2 mRNA and thus elicit a strong reduction of NRF2 protein and mRNA levels, and sensitize cells to anticancer drugs\textsuperscript{298}. However, subsequent studies provided conflicting results as they report that luteolin is an NRF2 activator\textsuperscript{299,300}. Another flavonoid, wogonin, has also yielded conflicting results\textsuperscript{301,302}. The coffee alkaloid trigonelline inhibited the nuclear accumulation of NRF2 protein\textsuperscript{303} and reduced NRF2-dependent proteasome activity in several pancreatic cancer cell lines\textsuperscript{304}. Nevertheless, these effects need to be addressed in a wider range of cell types before being taken to preclinical studies.

Targeting the interaction between NRF2 and sMAF proteins might be a promising strategy. Thus, a quantitative high-throughput screen identified a thiazole-indoline compound as an NRF2 inhibitor, and medicinal chemistry optimization led to compound ML385 that was found to bind the C-terminal domain of NRF2 and interfere with the formation of the NRF2/sMAF protein heterodimer that is required for activation of ARE-driven gene expression\textsuperscript{305}. Further work is needed to determine if ML385 is selective for NRF2/sMAF interaction or also affects other basic-region leucine zipper transcription factors. Moreover, this compound elicits a reduction of NRF2 protein levels, and therefore additional mechanisms of NRF2 regulation may operate. Other NRF2 inhibitors with unknown mechanism of action include malabricone A\textsuperscript{306}, ochratoxin A\textsuperscript{307} and AEM1\textsuperscript{308}. However, these compounds do not appear to be specific for NRF2 inhibition either.

\textbf{Acknowledgements}

This work was supported by Grants SAF2015-71304-REDT, SAF2016-76520-R, of the Spanish Ministry of Economy and Competiveness; P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020;
NIH grant R35 CA197222; Cancer Research UK grant C20953/A18644; Medical Research Council grant MR/N009851/1; Biotechnology and Biological Sciences Research Council grant BB/L01923X/1; Tenovus Scotland grant T17/14, grant 275147 from The Academy of Finland, Sigrid Juselius Foundation, Finnish Cancer Organizations.

**Glossary terms**

**Antioxidant Response Element (ARE)**

Specific DNA sequences, which are present in the promoter regions of NRF2-target genes. The ARE was discovered before NRF2, and its name originates from the fact that it was first identified in the promoter regions of genes that are induced by phenolic antioxidants.

**Autophagosome**

A spherical double-layer membrane structure with the cell. The autophagosome is the key structure in macroautophagy, a type of intracellular degradation process.

**Clara cells**

Dome-shaped cells found in the bronchioles of the lungs.

**Chronic Obstructive Pulmonary Disease**

Progressive lung disease including emphysema, chronic bronchitis, and refractory (non-reversible) asthma.

**Emphysema**

Progressive lung disease that causes shortness of breath due to over-inflation of the alveoli.
**Alport Syndrome**

Genetic disorder of the glomerular basement membrane, part of the glomerular filtration unit, characterized by kidney disease, hearing loss, and eye abnormalities.

**Gluconeogenesis**

Metabolic process that generates glucose from non-carbohydrate carbon substrates, such as lactate, glycerol, and glucogenic amino acids.

**Interferonopathies**

Mendelian disorders associated with an upregulation of interferon.

**Proteostasis**

Protein homeostasis.

**Redox stress**

An imbalance between oxidants and antioxidants in favor of the oxidants, leading to a disruption of redox signaling and control, and/or molecular damage.

**Abbreviations**

AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; ARE, antioxidant response element; BACH1, broad complex, tramtrack and bric à brac and cap’n’collar homology 1; BARD, bardoxolone methyl; BTB, Bric-à-Brac domain of KEAP1; CKD, chronic kidney
disease; COPD, chronic obstructive pulmonary disease; CTD, connective tissue disease; DMF, dimethyl fumarate; FA, fatty acid; FRDA, Friedreich's ataxia; GAPDH glyceraldehyde-3-phosphate dehydrogenase; GSH, reduced form of glutathione; GST, glutathione S-transferase; HMOX1, heme oxygenase 1; IVR, intervening region of KEAP1; KEAP1, Kelch-like ECH-associated protein 1; LC3, microtubule Associated Protein 1 Light Chain 3 Alpha; MMF, monomethyl fumarate; mtDNA, mitochondrial DNA; NADPH, reduced form of nicotinamide adenine dinucleotide phosphate; NF-kB, nuclear factor-kappaB; NO2-FA, Nitrated derivatives of fatty acids; NQO1, NAD(P)H:quinone oxidoreductase 1; NRF2, Nuclear factor (erythroid-derived 2) p45-related factor 2; PAH, pulmonary arterial hypertension; PD, Parkinson’s disease; PPI, protein-protein interaction; ROS, reactive oxygen species; SFN, sulforaphane; sMAF, small musculoaponeurotic fibrosarcoma oncogene homolog; SQSTM1, sequestosome 1; STING, stimulator of interferon genes; UBA, ubiquitin association domain of SQSTM1.

References

1 Moi, P., Chan, K., Asunis, I., Cao, A. & Kan, Y. W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 91, 9926-9930 (1994).

Identification of NRF2 as a member of the human cap’n’collar (CNC) basic-region leucine zipper transcription factor family.


Identification of NRF2 as the transcription factor that mediates the expression of cytoprotective genes through antioxidant response elements.

3 Chan, K., Lu, R., Chang, J. C. & Kan, Y. W. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci U S A 93, 13943-13948 (1996).


**Describes the identification of KEAP1 as the main negative regulator of NRF2.**


**Describes that KEAP1 functions as a substrate adaptor protein for Cul3-dependent ubiquitination of Nrf2.**


**Describes that KEAP1 functions as a substrate adaptor protein for Cul3-dependent ubiquitination of Nrf2.**


**Describes that KEAP1 functions as a substrate adaptor protein for Cul3-dependent ubiquitination of Nrf2.**


**The first attempt to address the role of NRF2 in human chronic disease from a systems medicine perspective; includes a map of disease mechanisms underlined by NRF2 alterations, the NRF2-diseasome, and a connectivity map of NRF2 with other physically or functionally associated proteins, the NRF2-interactome.**


**Comprehensive review of the cyanoneone triterpenoids and their broad applicability for prevention and treatment of chronic disease.**


**Describes that KEAP1 has distinct cysteine sensors.**


Describes the role of NRF2 in regulating the pentose phosphate pathway in cancer cells; provides the basis to understand how NRF2 participates in the metabolic alterations of cancer cells.

One of the earliest microarray analyses of the NRF2-dependent effects of sulforaphane in mice; identifies the importance of NRF2 in regulating the levels of NADPH.

Describes the role of NRF2 in regulating the pentose phosphate pathway in cancer cells; provides the basis to understand how NRF2 participates in the metabolic alterations of cancer cells.

Transcriptomic and proteomic profiling of KEAP1 disrupted and wild-type human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. *Carcinogenesis* 30, 1571-1580, doi:10.1093/carcin/bgp176 (2009).


One of the first studies that describes the role of NRF2 in regulating mitochondrial function.

One of the first studies that describes the role of NRF2 in regulating the expression of p62.

One of the first studies that describes the role of NRF2 in regulating the expression of p62.

One of the first studies that describes the role of NRF2 in regulating autophagy.

Links NRF2 with endoplasmic reticulum (ER) stress.


One of the first studies showing the anti-inflammatory role of Nrf2.


Reports a novel mechanism of NRF2 in repressing the expression of pro-inflammatory genes.


One of the first studies to show associations between polymorphisms in the NFE2L2 gene and human disease.


One of the first studies to show beneficial effects of NRF2 targeting in human lung disease.


Describes the mechanism by which an endogenous electrophile connects immunometabolism with upregulation of NRF2 and suppression of inflammation in macrophages.


Describes that NRF2 suppresses antiviral immunity, which can be exploited therapeutically in oncolytic infection.


Analysis of polymorphisms in *NFE2L2*, the gene encoding NRF2, that are associated with human disease.


Demonstrates the significance of NRF2 in human inflammatory bowel disease.


Wasik, U., Milkiewicz, M., Kempinska-Podhorodecka, A. & Milkiewicz, P. Protection against oxidative stress mediated by the Nrf2/Keap1 axis is impaired in Primary Biliary Cholangitis. Sci Rep 7, 44769, doi:10.1038/srep44769 (2017).


Describes that pharmacological activation of NRF2 in obese and insulin resistant mice reversed insulin resistance, suppressed hepatic steatosis and fibrosis, and that these protective effects were due to inhibition of endoplasmic reticulum (ER), inflammatory, and oxidative stress.


Demonstrates the beneficial effects of targeting NRF2 for cardioprotection.


The first mouse model combining amyloidopathy and tauopathy with presence or absence of NRF2; demonstrates that NRF2 deficient mice exhibit pathway alterations common to patients with Alzheimer's disease.


Provides preclinical proof-of-concept indicating that DMF can be repurposed for the treatment of synucleinopathies, such as Parkinson’s disease.


Describes the mechanism by which activation of NRF2 promotes Kras-driven lung carcinogenesis and results in dependence on glutaminolysis, which can be therapeutically exploited.


Demonstrates that mice with constitutive NRF2 activation do not develop spontaneous tumours, but that the combined activation of the PI3K pathway and NRF2 promotes the development of lung cancer characterized by immunosuppressive microenvironment, which can be therapeutically exploited by use of immune checkpoint inhibitors.


Describes that NRF2 is activated by oncogenes to promote ROS detoxification.


Fox, R. J. et al. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc


The first study describing the identification of sulforaphane as a highly potent naturally occurring inducer of cytoprotective enzymes.


The first study that identified C151 as a major sensor cysteine in KEAP1.


One of the earliest studies that identified the cyanoenone triterpenoids as extremely potent NRF2 activators.


One of the earliest studies describing a small molecule that inhibits the KEAP1-NRF2 protein-protein interaction.


One of the earliest studies describing a small molecule that inhibits the KEAP1-NRF2 protein-protein interaction.


Chowdhry, S. et al. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32, 3765-3781, doi:10.1038/onc.2012.388 (2013).


Demonstrated that broccoli sprout beverages can be used as frugal medicine to accelerate the detoxification of airborne pollutants in humans.


Reports the crystal structure of the BTB domain of KEAP1 in complex with a cyanoenone triterpenoid.


One of the earliest studies showing that NRF2 regulates genes involved in lipid metabolism.


One of the first studies to identify an NRF2 inhibitor.


Table 1. Summary of the NRF2 drug discovery pipeline sponsored by biopharmaceutical companies. Abbreviations: ALS, amyotrophic lateral sclerosis; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CTD, connective tissue disease; ER⁺, estrogen receptor positive; FRDA, Friedreich’s ataxia; FTD, frontotemporal dementia; HD, Huntington’s disease; IgA, immunoglobulin A; ILD, interstitial lung disease; ND, neurodegenerative diseases; PAH, pulmonary arterial hypertension; PD, Parkinson’s disease; T2DM, type 2 diabetes mellitus.

<table>
<thead>
<tr>
<th>Company/ Molecule</th>
<th>Disease</th>
<th>Development stage</th>
<th>Comments</th>
<th>Trial /Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BIOGEN:</strong> Dimethyl fumarate (DMF)</td>
<td>Multiple Sclerosis</td>
<td>Marketed</td>
<td>First marketed NRF2-targeting drug. Commercial name Tecfidera. Approved by FDA in 2013.</td>
<td>PROTEC/ NCT01930708</td>
</tr>
<tr>
<td></td>
<td>Psoriasis</td>
<td>Marketed</td>
<td>Approved in Germany in 1994. Commercial name Fumaderm.</td>
<td>Ref. 309</td>
</tr>
<tr>
<td><strong>BIOGEN:</strong> ALK8700/BII089</td>
<td>Multiple Sclerosis</td>
<td>Phase 3</td>
<td>Prodrug of monomethyl fumarate. Evaluation of tolerability of ALKS8700 and DMF. Estimated completion in 2019.</td>
<td>EVOLVE-MS-2/ NCT03093324</td>
</tr>
<tr>
<td><strong>REATA PHARMACEUTICALS:</strong> Bardoxolone methyl (BARD, RTA402)</td>
<td>CTD-PAH</td>
<td>Phase 3</td>
<td>Leading synthetic triterpenoid. Efficacy and safety in CTD-PAH. Estimated completion in 2020.</td>
<td>CATALYST/ NCT02657356</td>
</tr>
<tr>
<td></td>
<td>Pulmonary hypertension-ILD</td>
<td>Phase 3</td>
<td>Leading synthetic triterpenoid. Long-term safety and tolerability in pulmonary hypertension. Estimated completion in 2021.</td>
<td>RANGER/ NCT03068130</td>
</tr>
<tr>
<td></td>
<td>Alport syndrome</td>
<td>Phase 2/3</td>
<td>Leading synthetic triterpenoid. Safety and efficacy. Estimated completion in 2019.</td>
<td>CARDINAL/ NCT03019185</td>
</tr>
<tr>
<td></td>
<td>Autosomal Dominant Polycystic Kidney Disease, IgA Nephropathy, Type 1 Diabetes, Focal Segmental Glomerulosclerosis</td>
<td>Phase 2</td>
<td>Leading synthetic triterpenoid. Safety and efficacy in patients with rare chronic kidney diseases. Estimated completion in 2019.</td>
<td>PHOENIX/ NCT03366337</td>
</tr>
<tr>
<td><strong>REATA PHARMACEUTICALS:</strong> Omaveloxolone (RTA408)</td>
<td>FRDA</td>
<td>Phase 2</td>
<td>Second-generation synthetic triterpenoid. Safety, efficacy, and pharmacodynamics. Estimated completion in 2020.</td>
<td>MOXIe/ NCT02255435</td>
</tr>
<tr>
<td><strong>KYOWA HAKKO KIRIN:</strong> Bardoxolone methyl (BARD, RTA402)</td>
<td>T2DM, CKD</td>
<td>Phase 2 (completed)</td>
<td>Leading synthetic triterpenoid. Demonstrated increases in directly-measured glomerular filtration rate. Received the Japanese SAKIGAKE Designation for the treatment of diabetic kidney disease.</td>
<td>TSUBAKI/ NCT02316821</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phase 3</td>
<td>Leading synthetic triterpenoid. Primary end point: time to onset of a ≥30% decrease in estimated glomerular filtration rate from baseline or end-stage renal disease. Estimated completion in 2022.</td>
<td>AYAME/ NCT03550443</td>
</tr>
<tr>
<td><strong>EVGEN PHARMA:</strong> SFX01</td>
<td>Subarachnoid Hemorrhage</td>
<td>Phase 2</td>
<td>Cyclohexirin-encapsulated sulfurophane. Safety, tolerability, pharmacokinetics and pharmacodynamics. Estimated completion in 2019.</td>
<td>SAS/ NCT02614742</td>
</tr>
<tr>
<td></td>
<td>ER⁺ Metastatic Breast Cancer</td>
<td>Phase 2</td>
<td>Cyclohexirin-encapsulated sulfurophane. Safety and efficacy when used in combination with aromatase inhibitors, tamoxifen and fulvestrant. Estimated completion in 2019.</td>
<td>STEM/ NCT02970682</td>
</tr>
<tr>
<td><strong>COMPLEXA:</strong> CXA10</td>
<td>Primary Focal Segmental Glomerulosclerosis</td>
<td>Phase 2</td>
<td>10-nitro-octadec-9-enolic acid, a regioisomer of nitro-oleic acid. Two titration regimens of oral CXA-10. Estimated completion in 2019.</td>
<td>FIRSTx/ NCT03422510</td>
</tr>
<tr>
<td>Company/Therapeutic</td>
<td>Disease</td>
<td>Stage</td>
<td>Description</td>
<td>Reference/ID</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------</td>
<td>-------</td>
<td>-------------</td>
<td>--------------</td>
</tr>
<tr>
<td>ARBOR PHARMACEUTICALS: XP23829</td>
<td>Pulmonary Arterial Hypertension</td>
<td>Phase 2</td>
<td>10-nitro-octadec-9-enoic acid, a regioisomer of nitro-oleic acid. Safety, efficacy and pharmacokinetics of CXA-10 on stable background therapy. Estimated completion in 2019.</td>
<td>PRIMEX/ NCT03449524</td>
</tr>
<tr>
<td>COLBY PHARMACEUTICALS: OT-551</td>
<td>Psoriasis</td>
<td>Phase 2 (completed)</td>
<td>Tepilamide fumarate. Positive results disclosed in 2015 on efficacy as a potential treatment for moderate-to-severe chronic plaque psoriasis.</td>
<td>NCT02173301</td>
</tr>
<tr>
<td>VTV THERAPEUTICS: HPP971</td>
<td>Dry Eye Macular Degeneration</td>
<td>Phase 2 (completed)</td>
<td>Tempol hydroxylamine prodrug. Positive results in safety and tolerability. OT-551 reduced vision loss and conserved visual acuity.</td>
<td>OMEGA/ NCT00485394</td>
</tr>
<tr>
<td>V CLINBIO: VCB-101</td>
<td>Immunological Disorders, Bone, Eye, Lung, Blood diseases</td>
<td>Preclinical</td>
<td>Inhibitor of BACH1 that induces expression of HMOX1 in and NRF2-dependent manner.</td>
<td>Ref. 264</td>
</tr>
<tr>
<td>V CLINBIO: VCB-102</td>
<td>Psoriasis</td>
<td>Preclinical</td>
<td>Glycerol conjugate of monomethyl fumarate and eicosapentaenoic acid</td>
<td><a href="https://www.vclinbio">https://www.vclinbio</a> LLC.com</td>
</tr>
<tr>
<td>GlaxoSmithKline: Compound A</td>
<td>COPD</td>
<td>Preclinical</td>
<td>Potent and selective PPI inhibitor of the KEAP1 Kelch/NRF2 interaction in human bronchial epithelial cells and COPD patients-derived lung cells.</td>
<td>Ref. 246</td>
</tr>
<tr>
<td>MOCHIDA: TFM-735</td>
<td>Multiple Sclerosis</td>
<td>Preclinical</td>
<td>Potent NRF2 inducer that inhibits inflammatory cytokine production and disease progression in mice with experimental autoimmune encephalomyelitis.</td>
<td>Ref. 237</td>
</tr>
<tr>
<td>C4X DISCOVERY: ML334 and derivatives</td>
<td>ND, T2DM, COPD</td>
<td>Preclinical</td>
<td>PPI inhibitors identified through a high-throughput screen using a fluorescence polarization assay.</td>
<td>Ref. 247</td>
</tr>
<tr>
<td>KEAPSTONE THERAPEUTICS: KEAP1 inhibitors</td>
<td>PD, ALS</td>
<td>Preclinical</td>
<td>Chemical series of KEAP1 inhibitors developed at the Sheffield Institute for Translational Neuroscience.</td>
<td><a href="https://www.keapstone.com">https://www.keapstone.com</a></td>
</tr>
<tr>
<td>DAIICHI SANKYO CO: RS9</td>
<td>Retinovascular disease</td>
<td>Preclinical</td>
<td>NRF2 activator derived from products of microbial transformation.</td>
<td>Ref. 310</td>
</tr>
<tr>
<td>ACLIPSE THERAPEUTICS: M102</td>
<td>ALS and other ND</td>
<td>Preclinical</td>
<td>Selective activator of NRF2 and HSF1 showing disease modifying effects in ALS.</td>
<td><a href="https://www.aclipsetherapeutics.com">https://www.aclipsetherapeutics.com</a></td>
</tr>
</tbody>
</table>
Table 2. Half-lives and functions of representative proteins whose genes are transcriptionally regulated by NRF2.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Product</th>
<th>Function</th>
<th>Half-life (h)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biotransformation and detoxification</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AHR</td>
<td>Aryl Hydrocarbon Receptor</td>
<td>Regulation of xenobiotic detoxifying genes</td>
<td>7.7-9.7</td>
<td>311</td>
</tr>
<tr>
<td>CYP1B1</td>
<td>Cytochrome P450, B1</td>
<td>Xenobiotic detoxification</td>
<td>16.57 ± 3.00</td>
<td>312</td>
</tr>
<tr>
<td>UGT1A1</td>
<td>UDP-Glucuronosyl Transferase 1, A1</td>
<td>Detoxification reactions based in glucuronidation of small lipophilic molecules</td>
<td>~10</td>
<td></td>
</tr>
<tr>
<td>GSTM1</td>
<td>Glutathione S-Transferase, Mu 1</td>
<td>Detoxification of carcinogens, therapeutic drugs, xenobiotics and electrophiles by conjugation with glutathione</td>
<td>44.69 ± 4.56</td>
<td>312</td>
</tr>
<tr>
<td>ABCB6</td>
<td>ATP-Binding Cassette, B6</td>
<td>Mitochondrial ABC transporter involved in heme synthesis</td>
<td>~24</td>
<td>314</td>
</tr>
<tr>
<td>ABCC1</td>
<td>ATP-binding Cassette, C1</td>
<td>Organic anion ABC transporter. Multi-drug resistance</td>
<td>37.15 ± 8.03</td>
<td>312</td>
</tr>
<tr>
<td>CBR1</td>
<td>Carbonyl Reductase 1</td>
<td>Reduction of quinones, prostaglandins, menadione, various xenobiotics.</td>
<td>52.92 ± 15.73</td>
<td>312</td>
</tr>
<tr>
<td>EPHX1</td>
<td>Epoxide Hydrolase 1</td>
<td>Detoxification of polycyclic aromatic hydrocarbons</td>
<td>27.79 ± 3.40</td>
<td>312</td>
</tr>
<tr>
<td>ALDH3A2</td>
<td>Aldehyde Dehydrogenase 3, A2</td>
<td>Detoxification of aldehydes generated by alcohol metabolism and lipid peroxidation</td>
<td>87.00 ± 17.27</td>
<td>312</td>
</tr>
<tr>
<td>ADH7</td>
<td>Alcohol Dehydrogenase, class 4</td>
<td>Detoxification of aliphatic alcohols, hydroxysteroids, and lipid peroxidation products.</td>
<td>47.93 ± 7.31</td>
<td>312</td>
</tr>
<tr>
<td>NQO1</td>
<td>NAD(P)H:Quinone Oxidoreductase 1</td>
<td>Reduction of quinones to hydroquinones</td>
<td>59.37 ± 13.54</td>
<td>312</td>
</tr>
<tr>
<td><strong>Antioxidant enzymes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GPX4</td>
<td>Glutathione Peroxidase 4</td>
<td>Detoxification of hydrogen peroxide, organic hydroperoxides, and lipid peroxides</td>
<td>~18</td>
<td>315</td>
</tr>
<tr>
<td>GSR1</td>
<td>Glutathione Reductase 1</td>
<td>Conversion of glutathione disulfide (GSSG) to the reduced glutathione (GSH)</td>
<td>43.87 ± 6.41</td>
<td>312</td>
</tr>
<tr>
<td>TXN1</td>
<td>Thioredoxin 1</td>
<td>Reduction of other proteins by cysteine thiol-disulfide exchange</td>
<td>53.28 ± 5.43</td>
<td>312</td>
</tr>
<tr>
<td>PRDX1</td>
<td>Peroxiredoxin 1</td>
<td>Reduction of hydrogen peroxide and alkyl hydroperoxides.</td>
<td>54.41 ± 3.62</td>
<td>312</td>
</tr>
<tr>
<td>SRXN1</td>
<td>Sulfiredoxin 1</td>
<td>Reduction of cysteine-sulfinic acid formed in peroxiredoxins</td>
<td>9.50 ± 1.72</td>
<td>312</td>
</tr>
<tr>
<td><strong>Carbohydrate metabolism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G6PD</td>
<td>Glucose-6-Phosphate Dehydrogenase</td>
<td>1- Production of NADPH though the conversion of glucose 6-phosphate to 6-phosphogluconate in the Pentose Phosphate Pathway</td>
<td>46.33 ± 7.43</td>
<td>312</td>
</tr>
<tr>
<td>PGD</td>
<td>6-Phosphogluconate Dehydrogenase</td>
<td>Production of NADPH though the conversion of 6-phosphogluconate to ribulose 5-phosphate in the Pentose Phosphate Pathway</td>
<td>51.26 ± 7.72</td>
<td>312</td>
</tr>
<tr>
<td>Gene</td>
<td>Description</td>
<td>Role</td>
<td>Value</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td><strong>TALDO1</strong></td>
<td>Transaldolase 1</td>
<td>Interconversion of monosaccharides in the Pentose Phosphate Pathway. It links this pathway to glycolysis.</td>
<td>63.58 ± 3.83</td>
<td></td>
</tr>
<tr>
<td><strong>TKT</strong></td>
<td>Transketolase 1</td>
<td>Interconversion of monosaccharides in the Pentose Phosphate Pathway. It links this pathway to glycolysis.</td>
<td>81.32 ± 11.44</td>
<td></td>
</tr>
<tr>
<td><strong>ME1</strong></td>
<td>Malic Enzyme 1</td>
<td>Production of NADPH through oxidative decarboxylation of malate to pyruvate.</td>
<td>363.84</td>
<td></td>
</tr>
<tr>
<td><strong>UGDH</strong></td>
<td>UDP-Glucose Dehydrogenase</td>
<td>Conversion of UDP-glucose to UDP-glucuronate for biosynthesis of glycosaminoglycans</td>
<td>37.24 ± 3.60</td>
<td></td>
</tr>
<tr>
<td><strong>Lipid metabolism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ACOT7</strong></td>
<td>Acyl-CoA Thioesterase 7</td>
<td>Long-chain acyl-CoA hydrolase</td>
<td>148.61</td>
<td></td>
</tr>
<tr>
<td><strong>ACOX1</strong></td>
<td>Acyl-CoA Oxidase 1</td>
<td>Peroxisomal fatty acid beta-oxidation</td>
<td>32.10 ± 4.02</td>
<td></td>
</tr>
<tr>
<td><strong>SCD2</strong></td>
<td>Stearoyl-CoA Desaturase-2</td>
<td>Synthesis of unsaturated fatty acids.</td>
<td>∼3.5</td>
<td></td>
</tr>
<tr>
<td><strong>Heme and iron metabolism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HMOX1</strong></td>
<td>Heme Oxygenase 1</td>
<td>Heme catabolism. Release of anti-inflammatory carbon monoxide and antioxidant redox cycling biliverdin</td>
<td>∼15</td>
<td></td>
</tr>
<tr>
<td><strong>BLVRA</strong></td>
<td>Biliverdin Reductase A</td>
<td>ROS detoxification through biliverdin/bilirubin redox cycle</td>
<td>56.05 ± 8.21</td>
<td></td>
</tr>
<tr>
<td><strong>BLVRA</strong></td>
<td>Biliverdin Reductase A</td>
<td>ROS detoxification through biliverdin/bilirubin redox cycle</td>
<td>42.66 ± 8.75</td>
<td></td>
</tr>
<tr>
<td><strong>FECH</strong></td>
<td>Ferrochelatase</td>
<td>Heme biosynthesis</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td><strong>FTL1</strong></td>
<td>Ferritin Light Chain</td>
<td>Storage of iron in a soluble and nontoxic state</td>
<td>30.74</td>
<td></td>
</tr>
<tr>
<td><strong>Mediators of inflammation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PLA2G7</strong></td>
<td>Phospholipase A2, group VII</td>
<td>Degradation of platelet-activating factor</td>
<td>6.14</td>
<td></td>
</tr>
<tr>
<td><strong>PTGR1</strong></td>
<td>Prostaglandin Reductase 1</td>
<td>Inactivation of leukotriene B4</td>
<td>90.68</td>
<td></td>
</tr>
<tr>
<td><strong>CEBPB</strong></td>
<td>CCAAT/Enhancer-Binding Protein β</td>
<td>Regulation of genes involved in immune and inflammatory responses</td>
<td>8.59</td>
<td></td>
</tr>
<tr>
<td><strong>Regulation of NRF2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>KEAP1</strong></td>
<td>Kelch-like ECH-Associated Protein 1</td>
<td>Negative feedback for regulation of NRF2 stability</td>
<td>12.7</td>
<td></td>
</tr>
<tr>
<td><strong>NFE2L2</strong></td>
<td>Nuclear Factor (Erythroid-derived 2)-Like 2, (NRF2)</td>
<td>Master regulator of cellular homeostasis (about 250 genes)</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td><strong>Protein degradation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LAMP2A</strong></td>
<td>Lysosome-associated membrane protein 2</td>
<td>Chaperone mediated autophagy</td>
<td>75–110</td>
<td></td>
</tr>
<tr>
<td><strong>SQSTM1</strong></td>
<td>Sequestosome 1 (p62)</td>
<td>Macroautophagy</td>
<td>6–24</td>
<td></td>
</tr>
<tr>
<td><strong>PSMB1</strong></td>
<td>Proteasome subunit beta type-1</td>
<td>Core subunit of the proteasome 20S</td>
<td>133</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1. Regulation of NRF2 by KEAP1 and its pharmacological targeting. A, Representation of a single particle electron microscopy image of the KEAP1 dimer (grey surface) \(^{13}\) with the crystal structures of the BTB domain (red ribbons; PDB Ref 5NLB) and Kelch-repeat domains (green ribbons; PDB Ref 1ZGK) \(^{241}\) inserted for illustrative purposes. The reactive cysteines C151 and C613 are shown as blue spheres. The precise positions of the C226, C278, and C288 are not known, but they are all located in the IVR domain of KEAP1. The KEAP1 homodimer binds NRF2 at two motifs with low affinity (29-DLG-31) and high affinity (79-ETGE-82) and targets this transcription factor for ubiquitination and proteasomal degradation. Current strategies to disrupt this interaction include: electrophiles that chemically modify sulphhydryl groups of at least cysteines C151, C273, and C288 in KEAP1; PPI inhibitors that alter the docking of NRF2 to KEAP1. B, Electrophiles modify cysteine residues in sensitive proteins. Since KEAP1 is very sensitive to thiol reaction, electrophilic compounds easily induce KEAP1 modification. The window that allows therapeutic KEAP1 modification in the absence of unspecific thiol modifications within other proteins is represented in the pink area.
Figure 2. Expression of KEAP1 and NRF2 messenger RNAs in human brain and blood. A, The mRNAs for KEAP1 and NFE2L2 are in the 64th and 98th percentile of abundance of the total transcriptome of the brain. Note that KEAP1 mRNA levels are lower than NFE2L2 mRNA levels as would be expected since KEAP1 protein has a slower turnover (Table 2). B, Differential distribution of the mRNA for KEAP1 and NFE2L2 in human gray matter from mature brain specimens after removal of meninges and blood clots. Both transcripts are higher in astrocytes and microglia compared to neurons. For A and B, data were obtained from the Brain-RNAseq database. FPKM, Fragments Per Kilobase Million. KDE, Kernel density estimation; for details see reference 326. These values are calculated using the function ‘density’ of the statistical software package ‘R’ (http://www.r-project.org/). C and D, The mRNA expression of KEAP1 and NFE2L2 in some hematopoietic cells. The size and color of the dots correlates with the abundance of either KEAP1 (C) or NFE2L2 (D) mRNAs. Again, mRNA encoding KEAP1 is less abundant than that for NRF2. The relative expression of KEAP1 is low in monocytes, neutrophils and lymphocytes and high in the erythroid lineage while NFE2L2 exhibits the opposite trend. For C and D, data were obtained from the normal hematopoiesis samples of the Bloodspot database 327.
Figure 3. A. Crystal structure of the KEAP1 BTB domain (from PDB Ref 5NLB; residues 49-180); the protein is shown as a dimer in a surface representation (left hand side blue, righthand side grey) with the visible C151 shown in purple. The electrophilic motif of selected C151-interactive ligands is indicated by a purple circle; B. Crystal structure of the Kelch domain of KEAP1 (from PDB Ref 4XMB; residues 322-609); the protein is shown in a surface representation and the sub-pockets of the protein-protein interface are colored as follows: P1 sub-pocket: red (residues 415, 461, 462, 478, 483, 508); P2: blue (363, 380, 381, 414); P3: yellow (364, 509, 556, 571, 602, 603); P4: green (334, 572, 577); P5: cyan (525, 530, 555). Sub-pocket occupancy for the ligands 1-4 was determined from crystal structures 4XMB (by analogy to the bis-amide analogue), 5FNU, 4L7B and 3VNH respectively.
Figure 4. Modulation of cancer risk according to status of NRF2. Low NRF2 levels result from aging decline, functional haplotypes of single nucleotide polymorphisms in the *NFE2L2* gene promoter and by microRNA regulation. At least three factors contribute to increased risk of cancer initiation: uncontrolled redox signaling, increased exposure to oxidant genotoxicity, and dampened detoxification of environmental carcinogens. By contrast, over-activation of NRF2 by somatic mutations in *NFE2L2* or *KEAP1* or by collaboration with the indicated oncogenic signaling pathways increase NRF2 levels and promote carcinogenesis because these cells have a selective advantage to survive high ROS levels as well as to resist chemo- and radiotherapy. Pharmacological activation of NRF2 for therapy of chronic diseases should not exceed the safe therapeutic window. At this time, there is no evidence that pharmacological agents can produce the persistent and strong effects equivalent to those of somatic mutations in *NFE2L2* and *KEAP1* but based on preclinical proof-of-concept studies dosing of specific NRF2 activators should be very carefully monitored in order to assess potential cancer risk.